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ABSTRACT OF THE DISSERTATION 
 
Neuropsychological Effects of Pomegranate Supplementation Following Ischemic Stroke 
 
by 
John A. Bellone 
Doctor of Philosophy, Graduate Program in Clinical Psychology 
Loma Linda University, September 2016 
Drs. Richard E. Hartman & Travis G. Fogel, Chairpersons 
 
Polyphenols are compounds found in fruits and vegetables that have antioxidant 
and anti-inflammatory properties.  Mounting evidence suggests that dietary polyphenol 
intake can reduce the detrimental effects of various disease processes, and pomegranates 
have frequently been examined because of their particularly high polyphenol content.  
Since stroke induces both oxidative stress and inflammation and is currently the leading 
cause of long-term disability in the U.S., we sought to determine whether dietary 
supplementation with polyphenols could enhance cognitive recovery in individuals who 
had suffered an ischemic stroke.  We administered polyphenols via 2 POMx pills 
containing polyphenols derived from pomegranates equivalent to the content of 
approximately 8 ounces of pomegranate juice, or placebo pills (capsules containing no 
polyphenol ingredients), every day for one week to inpatients who were in the acute post-
stroke phase.  Neuropsychological testing pre- and post-treatment was used to determine 
whether there were any changes in cognitive functioning as a result of pomegranate 
supplementation.  Results trended toward subtle improvements in cognitive abilities in 
pomegranate-treated subjects compared to placebo-controlled subjects.  Findings from 
this randomized, placebo-controlled, double-blind clinical trial suggest that pomegranate 
 xiv 
polyphenols may be effective at enhancing the recovery of cognitive functioning after 
ischemic stroke, although studies with larger sample sizes and longer treatment durations 
are needed to make any conclusions regarding these potential effects. 
 
 1 
CHAPTER ONE 
INTRODUCTION 
 
Dietary supplementation with polyphenol-rich foods and beverages has received 
much attention from consumers and manufacturers over the past several years as a way to 
promote overall health, and has increasingly been investigated for its utility in preventing 
or improving a variety of disease states.  Foods rich in polyphenols include various types 
of fruits (e.g., strawberries, blueberries), vegetables (e.g., broccoli, red onions), legumes 
(e.g., lentils, fava beans), nuts (e.g., walnuts, pistachios), seeds (e.g., pumpkin and 
sunflower seeds), herbs (e.g., rosemary, sage), and spices (e.g., curry, cinnamon).  
Pomegranates (Punica granatum) contain particularly large amounts of polyphenols 
compared with other foods, with estimates of roughly 3 times the antioxidant activity of 
red wine and green tea (Gil, Tomás-Barberán, Hess-Pierce, Holcroft, & Kader, 2000).  
Their high phenol content has made them a target for studies investigating the health-
promoting qualities of polyphenols. 
Pomegranate polyphenols (PPs) have been touted for their antioxidant and anti-
inflammatory properties, and have been successfully shown to reduce the detrimental 
effects of many different disease processes.  For example, animal and clinical studies 
have demonstrated the efficacy of PPs in treating hypertension (Aviram & Dornfeld, 
2001), diabetes (T. H. W. Huang et al., 2005), depression-like behavior (Mori-Okamoto, 
Otawara-Hamamoto, Yamato, & Yoshimura, 2004), neonatal hypoxia-ischemia (Loren, 
Seeram, Schulman, & Holtzman, 2005; West, Atzeva, & Holtzman, 2007), prostate, 
breast, skin, and lung cancer (Afaq, Zaid, Khan, Dreher, & Mukhtar, 2009; G. N. Khan et 
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al., 2009; N. Khan, Afaq, Kweon, Kim, & Mukhtar, 2007; Paller et al., 2012), 
atherosclerosis (Aviram et al., 2000; de Nigris et al., 2005), coronary heart disease 
(Sumner et al., 2005), hyperlipidemia (Esmaillzadeh, Tahbaz, Gaieni, Alavi-Majd, & 
Azadbakht, 2004), microbial infections (Braga et al., 2005), rheumatoid arthritis (Balbir-
Gurman, Fuhrman, Braun-Moscovici, Markovits, & Aviram, 2011), and even erectile 
dysfunction (Azadzoi, Schulman, Aviram, & Siroky, 2005; Forest, Padma-Nathan, & 
Liker, 2007).  Dr. Hartman (committee co-chair) and colleagues have also had success in 
using pomegranate juice to ameliorate deficits in animal models of Alzheimer’s disease 
(Hartman et al., 2006) and exposure to proton radiation (Dulcich & Hartman, 2013). 
Although the beneficial effects of PPs have been well established for the 
prevention of various disease processes, and cognitive and emotional improvements are 
consistently shown in animal models, the effects of such compounds on cognitive 
functioning in humans are less established.  However, other polyphenol-laden foods and 
beverages, such as curry and green tea, may improve cognitive and emotional functioning 
in humans (Kuriyama et al., 2006; Ng et al., 2006).  Furthermore, two recent studies have 
shown promising findings using PPs, suggesting that they can improve memory 
functioning in a clinical population following cardiac surgery (Ropacki, Patel, & 
Hartman, 2013) and for individuals with mild memory complaints (Bookheimer et al., 
2013).  These results indicate the need for further investigation into the effects of PPs on 
cognitive and emotional functioning in other types of disease processes. 
One disease state that leads to a particularly large societal burden and frequently 
results in considerable cognitive dysfunction is stroke.  An ischemic stroke is a 
cerebrovascular event that reduces or blocks the flow of blood (and thus also oxygen and 
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nutrients) to the brain, often resulting in temporary and/or permanent cellular damage.  
This damage occurs via many pathological processes following the event, although the 
main mechanisms include oxidative stress (El Kossi & Zakhary, 2000), inflammation (J. 
Huang, Upadhyay, & Tamargo, 2006), excitotoxicity (Castillo, Dávalos, & Noya, 1997), 
and apoptosis (Du, Hu, Csernansky, Hsu, & Choi, 1996).  For survivors, severe, 
debilitating cognitive deficits and emotional disturbances often remain, and long-term 
morbidity is the norm in this population (Go et al., 2014). 
Approximately 800,000 Americans experience a new or recurrent stroke each 
year (Go et al., 2014), with a large percentage of survivors experiencing extensive 
cognitive deficits (M. D. Patel, Coshall, Rudd, & Wolfe, 2002; Tatemichi et al., 1994).  
The estimated cost of stroke to the U.S. in 2010 was 36.5 billion dollars, with the total 
medical costs projected to triple in the next two decades (Go et al., 2014).  Although 
there are hundreds of thousands of survivors each year (actual estimate is 670,500 
people), very few effective treatments are available to prevent or reduce the long-term 
debilitating effects.  Furthermore, although early initiation of medical and rehabilitation 
services, as well as rehabilitation in an interdisciplinary setting, drastically improves 
functional outcome (Cifu & Stewart, 1999; Salter, Hartley, & Foley, 2006; Paolucci et 
al., 2000), some degree of cognitive and adaptive deficits often remain following 
rehabilitation, and it has been estimated that only one-third of survivors receive such 
services (CDC, 2007). 
 Because PPs have demonstrated effectiveness in the treatment of pathological 
processes similar to those seen following stroke (e.g., oxidative stress, inflammation, 
excitotoxicity, and apoptosis), and because of their effectiveness at ameliorating various 
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other disease states, we hypothesized that PP intake would be an effective method of 
enhancing cognitive and emotional recovery following a stroke.  To our knowledge, this 
is the first study assessing the efficacy of PPs in a clinical stroke population, and one of 
few studies to use neuropsychological assessment methods to describe the progression of 
cognitive functioning following PP administration. 
 
Specific Aims and Hypotheses 
The present study was designed to assess the cognitive and emotional effects of 
pomegranate polyphenols (PPs) on patients who had suffered a recent ischemic stroke, as 
well as identify specific domains that may be differentially impacted. 
 
Aim 1: To Determine Whether PPs Improve Global Cognitive and/or Emotional 
Functioning in Individuals who have Experienced an Ischemic Stroke 
Data suggest that stroke results in long-lasting cognitive impairment, likely due to 
oxidative stress, inflammation, excitotoxicity, apoptosis, and numerous other deleterious 
processes (see Chapter 2).  Polyphenols can ameliorate each of these processes.  Mood 
symptoms are also prevalent after stroke as a result of both physical and psychosocial 
factors, and polyphenol intake has been shown to decrease these symptoms.  We 
hypothesized that PPs would be beneficial when administered shortly after a stroke, and 
would bolster cognitive recovery and decrease mood symptoms that are often 
experienced by stroke survivors.  Some positive change was also expected for the placebo 
group, since spontaneous recovery is common following stroke, but we hypothesized that 
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gains made by pomegranate-treated patients would exceed those made by placebo-
controlled patients. 
 
Specific Hypothesis 1 
Stroke patients who are administered PPs would have a higher degree of positive 
change (i.e., would perform better) on a post-treatment neuropsychological evaluation 
assessing global cognitive functioning (relative to their baseline functioning) than 
placebo controls.  More specifically, their RBANS Total Scale Index score and MMSE-2 
score (see Chapter 3 for description) would show more positive change than scores for 
controls.  Figure 1 depicts these hypothesized findings. 
 
 
Figure 1. Hypothesized effects of PPs on overall neuropsychological performance. 
RBANS: Repeatable Battery for the Assessment of Neuropsychological Status. 
MMSE-2: Mini-Mental State Examination – Second Edition 
 
 
 
Specific Hypothesis 2 
Stroke patients who took PPs would have a larger decrease in symptoms of 
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depression and anxiety on a post-treatment assessment (relative to their baseline 
functioning) than placebo controls.  More specifically, pomegranate-treated patients 
would endorse fewer depressive symptoms on the Beck Depression Inventory – Second 
Edition (BDI-II) and fewer anxiety symptoms on the State-Trait Anxiety Inventory 
(STAI; see Chapter 3 for description) relative to controls on post-treatment assessment.  
Figure 2 depicts these hypothesized findings. 
 
 
Figure 2. Hypothesized effects of PPs on emotional functioning. 
BDI-II: Beck Depression Inventory – Second Edition 
STAI: State-Trait Anxiety Inventory 
 
 
 
Aim 2: To Determine Whether PPs Differentially Affect Cognitive Domains 
Although the profile of cognitive deficits seen following stroke is often highly 
variable and largely depends on the lesion location (see Chapter 2), decrements may 
show patterns of variation by cognitive domain.  We hypothesized that domains most 
affected by stroke would be most improved by PPs, since they would leave the most 
room for improvement. 
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Specific Hypothesis 
Treatment with PPs would affect cognitive domains differently, where subjects 
that receive PPs would have larger improvements in the domains that changed most over 
time (see Figure 3). 
 
 
 
 
 Figure 3. Hypothesized effects of PPs on neuropsychological 
 performance with varying degrees of change per domain. 
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CHAPTER TWO 
REVIEW OF THE LITERATURE 
 
Polyphenols 
Claims for the benefits of consuming fruits and vegetables have tended to precede 
hypotheses as to the mechanism of their effects.  Many have suggested that these foods 
contain compounds that have effects independent of that of known nutrients (Arts & 
Hollman, 2005; Biesalski, 2007; Liu, 2003; Sun, Chu, Wu, & Liu, 2002).  Polyphenols, a 
subclass of phytochemicals that are abundant in a variety of plants and have many unique 
qualities, are a promising candidate. 
The term “polyphenols” refers to the large family of phenol structural units 
formed by attaching one or more hydroxyl group (i.e., oxygen atom connected by a 
covalent bond to a hydrogen atom) to one or more aromatic phenyl rings (see Figure 4 for 
a depiction of common polyphenol structures).  These bioactive compounds are found in 
most plant families and are an integral part of a plant’s physiology (e.g., provide 
pigmentation).  They are involved in development and reproduction, prevent decay, and 
provide protection from predators, pathogens, and ultraviolet radiation (Bravo, 1998; 
Hart & Hillis, 1974).  Polyphenols can be divided into over 10 major classes, each with 
numerous divisions and subdivisions.  For example, the flavonoids category can be 
divided into over 8000 different types of polyphenols (Quideau, Deffieux, Douat‐
Casassus, & Pouységu, 2011).  Humans mainly consume polyphenols in the phenolic 
acid and flavonoid classes, and, to a lesser extent, lignans and stilbenes.  Due to the large 
number of diverse compounds present in different foods, it is difficult to evaluate the 
effectiveness of individual phenols.  To review the phenolic breakdown of many different 
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types of foods, please visit the following website: http://www.phenol-explorer.eu/ (Neveu 
et al., 2010). 
 
 
Figure 4. Depiction of A) the simplest phenolic compound, containing one six-member 
carbon ring and one hydroxyl group, and B) ellagic acid, one polyphenol structure 
commonly found in pomegranate juice/extract. 
 
There has been an eruption of research on the salutary effects of polyphenols in 
the past two decades.  As aforementioned (see Chapter 1), a variety of polyphenol-rich 
foods have been demonstrated to prevent or improve pathological processes involved in 
many disease states, including cognitive and psychiatric symptoms (Gomez-Pinilla & 
Nguyen, 2012; Z. Huang et al., 2011; Kuriyama et al., 2006; Mori-Okamoto et al., 2004; 
Xu et al., 2006).  Although the main purported mechanisms by which polyphenols relay 
their benefits are likely through the reduction of oxidative stress and inflammation, they 
also affect apoptosis, neuroplasticity, and hemodynamics; modulate a broad array of 
receptors and enzymes (Manach, Scalbert, Morand, Rémésy, & Jiménez, 2004); protect 
against excitotoxicity (Castillo et al., 1997); reduce the probability of infection due to 
their antiproliferative/antimicrobial effects (Seeram et al., 2005); and have 
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gastroprotective effects via the modulation of nitrite and nitric oxide (Dykhuizen et al., 
1996; Rocha, Gago, Barbosa, & Laranjinha, 2009).  Another promising, albeit somewhat 
counter-intuitive, mechanism may be through hormesis, or pre-conditioning of the 
biological system with a mildly toxic agent.  These mechanisms are further discussed 
below. 
 
Bioavailability 
Bioavailability refers to the amount of ingested polyphenols that is absorbed and 
becomes available at a site of action.  Many factors limit polyphenol bioavailability, such 
as gastrointestinal degradation, first pass metabolism, poor solubility, insufficient 
permeability, and instability (Ratnam, Ankola, Bhardwaj, Sahana, & Kumar, 2006).  
Despite relative similarities, the different varieties of polyphenols can have widely 
varying pharmacokinetic properties (Manach et al., 2004).  Furthermore, the distribution 
of polyphenol category depends on the type of food, geological location, and method of 
processing (e.g., culinary preparation methods, such as cooking or peeling the skin from 
fruits and vegetables can substantially reduce polyphenol content; D'Archivio et al., 
2007).  Different properties, concentrations, and interactions among polyphenols 
simultaneously consumed make it extremely difficulty to get an accurate measure of 
typical bioavailability.   
Although not studied extensively, evidence (e.g., antioxidant capacity and 
plasma/urine concentrations) suggests that a portion of polyphenols get absorbed through 
the gut epithelium (Young et al., 1999; refer to D'Archivio et al., 2007, Table 1, for a 
review of the bioavailability of different types of polyphenols and foods).  Once 
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absorbed, the compounds are widely distributed throughout the body (see Lewandowska, 
Szewczyk, Hrabec, Janecka, & Gorlach, 2013, Figure 1, for a pharmacokinetic schematic 
of polyphenols).  Common metabolites of polyphenols, such as microbiota-derived 
urolithins, are also circulated throughout the body and have relatively strong antioxidant 
and anti-inflammatory properties (Bialonska, Kasimsetty, Khan, & Ferreira, 2009; 
Larrosa et al., 2010). 
Despite initial uncertainty regarding the capacity of polyphenols to cross the 
blood-brain barrier, it is now clear that a variety of polyphenols and their metabolites 
reach the brain (Datla, Christidou, Widmer, Rooprai, & Dexter, 2001; El Mohsen et al., 
2002; Youdim et al., 2003; Y.-J. Zhang et al., 2011).  Furthermore, they have been shown 
to accumulate in concentrations that are sufficiently high to confer neurological benefits 
(Spencer, 2010; Williams, Spencer, & Rice-Evans, 2004), such as reduced pathology and 
improved learning and memory ability (Andres-Lacueva et al., 2005; J. Wang et al., 
2012).  Even if they did not directly modify the central nervous system (CNS), 
polyphenols could exert their benefits by altering signaling pathways from peripheral 
organs to the CNS (thus improving cerebral blood flow) and by influencing influx and 
efflux mechanisms at the blood-brain barrier (Schaffer & Halliwell, 2012). 
 
 
Mechanisms of Action 
Oxidative Stress 
Polyphenols have long been known for their antioxidant properties.  Like vitamin 
C, vitamin E, and carotenoids, polyphenols are reducing agents, and protect bodily tissues 
from oxidative stress (Scalbert & Williamson, 2000).  Oxidative stress is a deleterious 
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state that results from an imbalance in the reactive intermediate forms of O2, collectively 
known as reactive oxygen species (ROS; e.g., free radicals and peroxides).  Although 
maintaining a certain level of ROS is crucial to biological systems, an excess, such as that 
caused by various disease states, can lead to cellular pathology and death (Evans & 
Cooke, 2004).  Unfortunately, the brain has relatively low levels of endogenous 
antioxidant enzymes and is typically unable counteract these imbalances (Rossi, 
Mazzitelli, Arciello, Capo, & Rotilio, 2008). 
Antioxidants, such as polyphenols, work by trapping and scavenging free radicals 
(atoms or molecules with a missing electron).  Providing an electron to these radicals 
prevents them from going on to pilfer electrons from other atoms, which could otherwise 
lead to the oxidation and damage of membrane lipids, proteins, enzymes, carbohydrates, 
DNA, and RNA (Bandyopadhyay, Das, & Banerjee, 1999).  Antioxidants also provide 
stability to peroxides (unstable compounds with an oxygen-oxygen chemical bond) that 
split into reactive radicals (Marcus et al., 1998).  Furthermore, the rapid donation of a 
hydrogen atom to radicals interferes with the lipid oxidation process.  This antioxidant 
capacity to inhibit low-density lipoprotein oxidation reduces the accumulation of arterial 
cholesterol deposits, thereby reducing atherosclerosis (Ismail, Sestili, & Akhtar, 2012; 
Serafini, Laranjinha, Almeida, & Maiani, 2000).  The anti-atherogenic characteristics of 
polyphenols are also due to their ability to upregulate other antioxidant factors (Khateeb, 
Gantman, Kreitenberg, Aviram, & Fuhrman, 2010).  A similar mechanism (i.e., reduction 
of ROS) is likely partially responsible for the anti-carcinogenic effects of polyphenols 
(Ismail et al., 2012). 
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Although there are many sources of antioxidants in our diets, polyphenols are the 
most abundant (Scalbert & Williamson, 2000).  However, the antioxidant characteristics 
greatly depend on the specific type of polyphenol (i.e., its chemical structure).  For 
example, flavonoids are more potent antioxidants than other polyphenol classes because 
of their unique structural elements (Bravo, 1998).  They also prevent reactions that would 
lead to increased levels of ROS (Fuhrman, Lavy, & Aviram, 1995).  The antioxidant 
qualities of polyphenols depend on their rate of absorption, with certain subclasses 
exhibiting greater effects because they are less soluble and get digested slowly, thus 
remaining in the digestive tract longer and prolonging their antioxidant activity 
(Hagerman et al., 1998).  Although only a small portion of polyphenols from food are 
actually absorbed and digested, it has been shown that even very low levels are sufficient 
to provide antioxidant effects (Serafini, Ghiselli, & Ferro-Luzzi, 1996). 
 
 
Inflammation 
Although the beneficial effects of polyphenols have long been attributed to their 
ability to reduce oxidative stress, recent attention has shifted to their anti-inflammatory 
properties.  Inflammation is a feature of the complex biological response to noxious 
stimuli.  It can be acute or chronic, and involves a cascade of events that include the 
body’s vascular and immune systems (Schauss, 2013).  At the first sign of an injury or 
infection, pattern recognition receptors on cells release inflammatory mediators that 
dilate blood vessels and signal the migration of leukocytes (i.e., white blood cells) to the 
site of injury.  Leukocytes play a role in the initiation and maintenance of the 
inflammatory response, and some of them act as phagocytes, removing cellular debris.  
 14 
The vasodilation increases blood flow to the area, up-regulating plasma fluid that 
contains important proteins. 
Although the inflammatory response is initially adaptive and promotes healing, its 
persistence can be destructive and is implemented in many disease processes (e.g., 
cancer, neurodegenerative diseases, diabetes).  The acute phase of the response lasts 
minutes to hours, until the area of injury is returned to homeostasis.  In chronic (or 
systemic) inflammation, the acute phase persists for weeks, days, or even years, resulting 
in the increased production of ROS (and thus oxidative stress), enzymes, growth factors, 
and cytokines that contribute to cell damage and death (Schauss, 2013). 
One particular mechanism that propagates the chronic inflammatory response is 
via a protein complex responsible for DNA transcription, named NF-KB.  ROS and other 
harmful stimuli activate NF-KB, which can rapidly alter gene expression and enhance the 
immune response (by way of T-cell up-regulation; Gilmore, 2006).  Thus, a maladaptive 
cycle ensues, whereby ROS increase the inflammatory response that, in turn, increases 
levels of ROS.  This leads to the continuous activation of NF-KB and the chronic, 
deleterious immune/inflammatory response. 
A growing body of evidence has demonstrated the effectiveness of polyphenols in 
reducing the inflammatory process involved in various disease states, although the 
mechanisms by which it accomplishes this are still largely unknown.  One of the main 
ways polyphenols reduce chronic inflammation is likely by down-regulating the 
expression of pro-inflammatory biomarkers (e.g., NF-KB) that maintain the immune 
response (Biesalski, 2007; Gonzalez et al., 2011).  For example, one study showed that a 
variety of polyphenol-containing plant extracts modulate NF-KB and attenuate disease-
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related activity (Paur, Austenaa, & Blomhoff, 2008).  Another study found that the cycle 
of ROS-inflammation could be blunted by the polyphenols in turmeric and red wine 
(Rahman, Biswas, & Kirkham, 2006).  Furthermore, it is likely that the antioxidant 
properties of polyphenols can reduce inflammation via a decrease in ROS and oxidative 
stress, suggesting that their antioxidant and anti-inflammatory properties are intimately 
linked. 
 
 
Apoptosis 
Apoptosis is a genetically controlled process of programmed cell death that is 
essential for proper development and continued homeostasis throughout an organism’s 
life.  However, the malfunction of this process (i.e., too much or too little apoptosis) is 
involved in a range of pathologies, from degenerative diseases to cancer.  Polyphenols 
modulate apoptosis, which adds to their utility as therapeutic agents (Giovannini & 
Masella, 2012).  Although generally touted for their anti-apoptotic qualities that are 
largely associated with their antioxidant properties (Chao, Hou, Chao, Weng, & Ho, 
2009; Chen et al., 2012; Kairisalo et al., 2011), polyphenols can also induce apoptosis.  
Whether they act as anti-apoptotic or pro-apoptotic agents depends on a variety of 
factors, such as the concentration, disease type or stage, and cell system (Giovannini & 
Masella, 2012; Loo, 2003). 
The pro-apoptotic qualities of polyphenols make them chemopreventive, and 
numerous studies have found reductions in cancer cell proliferation and tumor growth 
following polyphenol administration (N. Khan et al., 2007; Koyama et al., 2010; Seeram 
et al., 2005).  Although the specifics are largely unknown, several potential mechanisms 
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have been identified to explain these properties.  Cancer cells, especially the aggressive, 
invasive types, rely on consistent amounts of ROS (particularly hydrogen peroxide) and 
are sensitive to changes in ROS levels (Loo, 2003).  Since conditions of moderate 
oxidative stress increase cancer cell survival potential and proliferation (Arora-Kuruganti, 
Lucchesi, & Wurster, 1999; Del Bello, Paolicchi, Comporti, Pompella, & Maellaro, 
1999), the antioxidant properties of polyphenols may reduce ROS levels to a point that 
triggers apoptosis (Seeram et al., 2005).  In contrast, polyphenols have paradoxically 
been shown to selectively increase oxidative stress in cancer cells while sparing healthy 
normal cells (Babich, Pinsky, Muskin, & Zuckerbraun, 2006; Cheng et al., 2010; Feng et 
al., 2007).  Part of these seemingly paradoxical properties may be due to a difference 
between the chemical and biological definitions of an “antioxidant” (Forman & Ursini, 
2011).  Specifically, the commonly used biological definition is relatively broad and 
refers to any process that protects against oxidative stress, regardless of the mechanism. 
 
 
Neuroplasticity 
Different types of fruits and teas have been assessed for their utility in promoting 
neuroplasticity (i.e., synaptic and structural modifications in the brain).  Short-term 
blueberry supplementation, for example, has been shown to increase different parameters 
of hippocampal neuronal plasticity in aged rats (Casadesus et al., 2004).  A grape 
polyphenol preparation comprising grape seed extract, Concord purple grape juice 
extract, and resveratrol also showed promise, rescuing the long-term potentiation (LTP; 
i.e., the activity-dependent increase in synaptic efficacy) deficits found in a diet-induced 
animal model of metabolic syndrome (J. Wang et al., 2013).  Additionally, one 
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polyphenol-rich component in green tea (i.e., EGCG) has led to enhanced levels of LTP, 
both in hippocampal slices from normal mice and in a Down’s syndrome mouse model 
(Xie, Ramakrishna, Wieraszko, & Hwang, 2008).  LTP was similarly promoted following 
administration of an extract from a traditional Chinese herb (i.e., Polygonum multiflorum; 
T. Wang et al., 2011). 
Curcumin, a polyphenol-laden spice found in turmeric, was shown to incorporate 
into neural stem cells and induce neurogenesis (i.e., the birth of new neurons) in the 
dentate gyrus of the hippocampus (S. Kim et al., 2008; Tiwari et al., 2013).  Curcumin 
also has neuroprotective effects that are likely mediated by its ability to increase brain-
derived neurotrophic factor (BDNF), a growth factor involved in initiating several 
neuroplastic processes (R. Wang et al., 2008; R. Wang et al., 2010).  For example, it has 
protected against the deleterious effects of traumatic brain injury on markers of 
neuroplasticity (Wu, Ying, & Gomez-Pinilla, 2006) and prevented a stress-induced 
decrease in BDNF (Xu et al., 2006), as well as increased hippocampal neurogenesis in 
this stress-induced model (Xu et al., 2007).  It is thought that this polyphenol-induced 
increase in BDNF is one of the mechanisms behind its antidepressant properties (Z. 
Huang et al., 2011); the other proposed mechanism being increased serotonin and 
dopamine through the inhibition of monoamine oxidase enzymes (Kulkarni, Dhir, & 
Akula, 2009; Kulkarni, Bhutani, & Bishnoi, 2008). 
 
Hemodynamic Effects 
Several recent studies have suggested that polyphenols have an effect on 
hemodynamic forces (i.e., the circulation of blood flow).  For example, both pomegranate 
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juice and supplements (i.e., POMx) reduce platelet activation (Mattiello, Trifirò, Jotti, & 
Pulcinelli, 2009), making blood less likely to clot.  Many authors have attributed the 
resulting increased blood flow as one of the main mechanisms by which polyphenols 
(especially from pomegranates) confer their cardiovascular health benefits (Cordier & 
Steenkamp, 2012; Phang, Lazarus, Wood, & Garg, 2011; Stoclet et al., 2004).  By 
preventing or reducing the cerebrovascular compromise that results from atherosclerosis, 
hypertension, diabetes, and hyperlipidemia, polyphenol-mediated hemodynamic changes 
would likely reduce rates of numerous adverse events, such as stroke (Ghosh & 
Scheepens, 2009). 
 
 
Hormesis 
 As aforementioned, some types of polyphenols are toxic to predators (e.g., leaf-
eating insects) and pathogens and therefore protect plants from harm (Son, Camandola, & 
Mattson, 2008).  This may be the reason why polyphenols tend to be concentrated in 
vulnerable areas of plants, such as their roots, leaves, and the rind or skin of their fruit 
(Mattson, 2008a; Mattson & Cheng, 2006).  One potential mechanism for the benefits of 
polyphenols that has been gaining support in recent years is the possibility that human 
ingestion of polyphenols may initiate a process of increased energy demand, mild level of 
free radical production, and ion fluxes that “exercises” the cellular stress response and 
improves its ability to defend against subsequent stressors (Son et al., 2008).  This 
concept is known as “hormesis,” or pre-conditioning, and has been postulated to also 
mediate the health benefits of caloric restriction/intermittent fasting (Mattson, 2008a) and 
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subtoxic radiation exposure (i.e., “radiation hormesis”; Gori & Münzel, 2011), among 
other usually harmful agents (Rattan, 2008).   
The process involves a biphasic dose-response relationship (i.e., has a J-shaped or 
U-shaped curve), meaning there is a dose range where polyphenols may have hormetic 
properties (Chirumbolo, 2011; Mattson, 2008b; Son et al., 2008).  Mechanisms of action 
differ based on polyphenol type and cell variety, but involves the regulation of 
transcription factors, signaling kinases, and protein expression in an adaptive fashion 
(Mattson & Cheng, 2006; Mattson, Son, & Camandola, 2007).  A related concept is the 
“xenohormesis hypothesis,” which proposes that our cells can “sense” the potential 
impending stress responses from food sources (i.e., the accumulation of polyphenols) and 
trigger the hormetic response (Baur & Sinclair, 2006). 
 
 
Pomegranates 
Pomegranates have been consumed since the beginning of recorded history, being 
seen as a symbol of divine femininity and fertility (Lansky, Shubert, & Neeman, 2000).  
They were extolled by the Greeks, Egyptians, Babylonians, Jews, Persians, and Chinese 
for their mystical and medicinal properties (Lansky et al., 2000).  It has been documented 
that many cultures have used the fruit as a treatment for leprosy (Singh, Sharma, & 
Khare, 1980), snake bites (Jain & Puri, 1984), intestinal worms (Naqvi, Khan, & Vohora, 
1991; Wren, 1988), assorted gynecological issues (Singh et al., 1980), burns (Siang, 
1983), and diarrhea (Boukef, Souissi, & Balansard, 1982), among others.  Although many 
of the previous notions and applications of the pomegranate fruit are no longer popular, 
 20 
the full extent of health-promoting qualities of pomegranates is just beginning to be 
discovered. 
Although there are numerous foods that contain large amounts of polyphenols, 
pomegranates have a particularly large amount and variety of phenol compounds (Gil et 
al., 2000; Seeram et al., 2008).  For example, they contain punicalagins, anthocyanins, 
and ellagic acid (of the phenolic acids class), as well as various types of tannins (of the 
flavonoids class).  It has also been suggested that the effects of pomegranate juice may be 
better attributed to the metabolic by-products of its polyphenols by colonic microflora 
(microbes in the gut), rather than just to the polyphenols themselves (Cerdá, Espín, Parra, 
Martínez, & Tomás-Barberán, 2004).  Furthermore, the effects of individual phenols and 
their metabolites may be enhanced when combined with other phenols, leading to a 
synergistic effect (Seeram et al., 2005).  Evidence also suggests that the whole fruit (with 
rind and husk included) is better than just juice from the arils (Gil et al., 2000).  This is 
how commercial pomegranate juice and supplements of the Wonderful variety, such as is 
being utilized in the present study, are made. 
As aforementioned, the beneficial effects of pomegranate juice have been well 
established for dozens of different disease states (see Chapter 1).  Pomegranate 
polyphenols (PPs) are known to be potent antioxidants and anti-inflammatory agents, and 
it is believed that these are just a couple of the mechanisms by which they confer their 
health benefits (Gil et al., 2000; Ismail et al., 2012; see above for a discussion regarding 
other mechanisms).  These biological benefits ultimately lead to improvements in 
cognitive functioning, as has been demonstrated in a number of recent animal studies.  
For example, one study used pomegranate flowers to improve learning and memory 
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performance and decrease oxidative stress in diabetic rats (Cambay, Baydas, Tuzcu, & 
Bal, 2011).  Other studies have assessed the effects of PPs on memory and Alzheimer’s 
disease (AD)-like pathology.  In a study using transgenic AD (APPsw/TG2576) mice, it 
was found that mice fed a diet containing 4% pomegranate extract for over one year had 
improved learning, memory, and locomotor functioning, and decreased anxiety levels, as 
compared with transgenic AD mice on a normal diet (Subash et al., 2014).  Another study 
used pomegranate seed extract to reduce retention deficits in aged mice (Kumar, 
Maheshwari, & Singh, 2009). 
As previously noted, Dr. Hartman has experience studying the effects of PPs on 
behavior and cognition.  For example, his study was the first to demonstrate the 
effectiveness of PPs in a transgenic mouse model of AD, where mice that were 
administered PPs had half the plaque load and showed improved learning abilities 
compared with transgenic controls (Hartman et al., 2006).  His team also studied the 
effects of PPs on behavior in mice shortly after exposure to a low dose of proton 
radiation.  Although no learning or memory differences were found (likely due to the 
minimal short-term effects of a low dose of proton radiation), the group administered PPs 
showed decreased depression-like behavior and improved balance and coordination 
(Dulcich & Hartman, 2013).  It is important to note that there were greater effects on 
male mice than on female mice, possibly because polyphenols exhibit phytoestrogen 
activity (Cos et al., 2003).  A recent pilot study Dr. Hartman’s team conducted in a 
clinical population undergoing heart surgery showed that PPs can be used to prevent 
memory retention deficits commonly seen following this type of procedure (Ropacki et 
al., 2013).  Another lab also recently conducted a pilot study on the effects of PPs on 
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cognition.  Their findings showed that, after 4 weeks of administering PPs to a group of 
older adults with age-associated memory complaints, subjects who received PPs showed 
a significant improvement on a verbal memory test and had increased fMRI activity 
during verbal and visual memory tasks as compared with placebo controls (Bookheimer 
et al., 2013). 
 
 
Stroke 
Stroke is a cerebrovascular accident that results in a disruption of blood flow to 
the brain and subsequent neurological dysfunction.  This disruption can occur in the form 
of a reduction or complete blockage of blood flow (i.e., ischemia), or an excess of blood 
flow (i.e., hemorrhage).  Because neurons have a high metabolic rate compared with 
other types of cells, they are particularly susceptible to drastic changes in the level of 
oxygen and glucose (Attwell & Laughlin, 2001; Laughlin, van Steveninck, & Anderson, 
1998).  The hypo-perfusion (i.e., decreased blood flow) and nutrient deficiencies often 
lead to a cascade of events that result in neuronal damage and death in the immediate area 
and in the penumbra (i.e., area around the lesion that survives the infarct).  First, there is a 
change in membrane potentials and ion concentrations (Martin, Lloyd, & Cowan, 1994).  
Specifically, the decrease in glucose causes the sodium-potassium pump to stop working 
due to a lack of energy availability, leading to an excess of sodium influx.  As the 
membrane potential falls toward 0 millivolts the extracellular concentration of excitatory 
amino acid neurotransmitters, such as glutamate, increase to toxic levels.  In a process 
termed “excitotoxicity” (Olney, 1969), this pathologically high glutamate concentration 
leads to increased gene transcription and neuronal over-activation that initiates the 
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apoptotic response.  Neuronal apoptosis has been shown to even occur in mild ischemic 
events (Du et al., 1996). 
Many other mechanisms also contribute to the behavioral and cognitive changes 
commonly observed after stroke.  For example, the creation of ROS results from the 
hemolytic disruption of covalent bonds after ischemic reperfusion and by the release of 
transition metal ions (Bandyopadhyay et al., 1999).  These go on to cause oxidative stress 
that can result in damage to proteins, lipid membranes, and DNA.  The increased ROS 
levels, activation of intracellular second-messenger systems (from cellular over-
activation), presence of cellular debris from necrosis brought about by excitotoxicity and 
apoptosis, and the hypoxic event itself can lead to the activation of pro-inflammatory 
transcription factors (i.e., NF-KB) that maintain chronic inflammation (Dirnagl, Iadecola, 
& Moskowitz, 1999; Sánchez-Moreno et al., 2004).  The inflammatory response, 
although most prominent approximately 5 to 7 days post event, can persist for months 
(Emsley et al., 2003).  As mentioned above, this chronic inflammation leads to increased 
oxidative stress and apoptosis and continues the pathological cycle. 
 
 
Cognitive and Psychological Effects 
Stroke survivors typically experience numerous cognitive and neurological 
changes.  Although the specific decrements depend largely on the location and size of 
cerebral infarction (Crafton, Mark, & Cramer, 2003; Ferro, 2001; Hillis et al., 2004), and 
there is a high degree of variability across individuals (Cramer, 2008a), certain patterns 
of behavioral deficits are common.  In one study, over 70% of patients demonstrated 
slowed information processing, and more than 40% had impairments in 
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visuospatial/constructive skills, memory, language functions, and arithmetic ability 
(Hochstenbach, Mulder, van Limbeek, Donders, & Schoonderwaldt, 1998).  Other studies 
have shown similar impairments in memory, language, attention, and orientation 
(Tatemichi et al., 1994), as well as deficits in higher-order cognitive abilities, such as 
abstract thinking, judgment, and comprehension (Galski, Bruno, Zorowitz, & Walker, 
1993).  Additional common deficits include anosognosia (i.e., lack of awareness of one’s 
impairments), apraxia (i.e., inability to perform learned movements), hemispatial neglect, 
and hemiparesis (i.e., contralateral physical weakness; Hier, Mondlock, & Caplan, 1983).  
Dysfunction can also occur in remote brain areas (termed “diaschisis”) that relied on 
connection with the now-damaged region (Y. Kim et al., 2005). 
In addition to cognitive effects, mood symptoms are quite common following 
stroke.  One study showed that 40% of stroke survivors developed mild depressive 
symptoms and 12% developed moderate to severe symptoms, which is much higher than 
national averages (Nys et al., 2005; see Hackett, Yapa, Parag, & Anderson, 2005) for a 
systematic review).  The severity of depression was strongly correlated with the degree of 
cognitive impairment, functional impairment, and lesion volume, while having no 
correlation with lesion location or demographic variables in that study.  Moderate to 
severe depression was closely tied to language, memory, and visual-perceptual 
impairments.  A follow up study showed that unilateral neglect was the greatest risk 
factor for depressive symptoms after stroke (Nys et al., 2006).  Cognitive impairment and 
functional dependence also predicted a reduction in quality of life.  Rates of anxiety 
disorders in this population are similar to rates of depression and interfere substantially 
with recovery (Åström, 1996). 
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Time Course 
 Many neuroplastic changes occur after a stroke, and some authors have broken 
the post-stroke period into three “epochs” based on common changes the brain undergoes 
at different time intervals (Cramer, 2008a).  The acute injury phase (i.e., initial hours to 
days after stroke) is referred to as the first epoch, when edema, inflammation, altered 
metabolism, and other changes are typically at their greatest.  The second epoch lasts for 
days to a few months post-stroke, and is the time period when most spontaneous recovery 
occurs.  During this period, the non-affected neurons in the area around the infarct send 
new branches toward the lesion site in an effort to re-organize connections and rescue 
function (C. Brown, Aminoltejari, Erb, Winship & Murphy, 2009).  Increases in BDNF 
(J. Chen et al., 2005), neurogenesis (Zhang, Zhang & Chopp, 2008), the formation of new 
synapses (Warraich & Kleim, 2010), and many other molecular and structural changes 
(Cramer, 2008a) are ongoing during this epoch.  Improvements in cognitive abilities 
typically follow a similar time course as the neuroplastic changes, with most cognitive 
and adaptive gains made in the first few months post-stroke (Jørgensen et al., 1995; 
Kwakkel, Kollen, & Twisk, 2006).  However, it is important to understand that the rate 
and extent of functional recovery varies somewhat based on the particular neurological 
domain (Cramer, Koroshetz, & Finklestein, 2007). 
The third epoch typically starts weeks to months after infarction, when 
neuroplastic changes tend to plateau and smaller, slower improvements are made.  
Although most of the neurological repair has already taken place, improvements in 
cognitive and adaptive functioning may continue for years.  However, despite the amount 
of spontaneous recovery and subsequent gains that are typical following stroke, most 
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individuals have long-lasting cognitive, emotional, and adaptive problems (M. Patel, 
Coshall, Rudd, & Wolfe, 2003).  For example, studies have shown that as few as 15% of 
stroke survivors return to their cognitive baseline one year post stroke (Desmond, 
Moroney, Sano, & Stern, 1996; Hofgren, Björkdahl, Esbjörnsson, & Stibrant‐
Sunnerhagen, 2007), with similarly low rates of gainful employment.  Regarding the time 
course of depression, rates decrease after the first few months post stroke, but then tend 
to increase within a couple years, mainly due to difficulties with activities of daily living, 
cognitive limitations, and decreased social connection (Åström, Adolfsson, & Asplund, 
1993).  Anxiety symptoms tend to remain relatively stable years after stroke (Åström, 
1996). 
 
 
Neuropsychological Testing 
 There are a variety of measures that are used clinically to assess cognitive and 
psychological functioning following stroke.  Unfortunately, few studies of stroke include 
any formal cognitive assessment, and many of those that do only include the Mini-Mental 
State Examination (MMSE).  Although measures like the MMSE can be valuable tools, 
some suggest that tests that provide domain-specific scores, rather than only a global 
index that lacks sensitivity, may be a better approach (Mysiw, Beegan, & Gatens, 1989).  
This was the rationale for selecting the many domain-specific tests used in the present 
study (see Chapter 3 for a description of each test used). 
Even brief neuropsychological batteries can provide valuable diagnostic and 
prognostic information to assist with treatment planning (Larson et al., 2003; Stewart, 
Gale, & Diamond, 2002), and they have recently been used to construct a cognitive 
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profile and predict recovery following stroke.  One recent study using the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS; Randolph, 1998; the 
primary outcome measure used in the present study) in stroke inpatients showed that the 
indices (i.e., the domain-specific scores) significantly predicted cognitive ability up to 6 
months after testing (Larson et al., 2003).  This indicates the utility of neuropsychological 
measures even in the acute post-stroke phase (i.e., the first epoch), before significant 
cognitive recovery has begun.  A follow up study demonstrated the ability of the RBANS 
to predict cognitive ability one year after subjects’ inpatient stay, with individual indices 
predicting instrumental activities of daily living (Larson, Kirschner, Bode, Heinemann, & 
Goodman, 2005). 
 
Current Treatments 
 There are currently several treatments that are either in use or in the process of 
being evaluated for stroke survivors, although their effectiveness and practicality are 
mixed.  One widely available treatment used to degrade arterial thrombi (typically blood 
clots that occlude arteries) is tissue plasminogen activator (tPA), although it has a very 
brief administration window with many contraindications (Katzan et al., 2004).  Research 
suggests that co-administering an anti-inflammatory agent (potentially PPs) with tPA 
reduces the probability of the drug leaking across the blood-brain barrier, where it is 
neurotoxic (L. Zhang et al., 2003).  Another promising clinical treatment is induced 
moderate hypothermia, which is believed to decrease the generation of ROS and 
attenuate neuronal cell death (Gluckman et al., 2005; Shankaran et al., 2005).  However, 
this technique has mainly been demonstrated effective in animal models of neonatal 
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ischemia/hypoxia, and is still in clinical trials (van der Worp, Macleod, & Kollmar, 
2010). 
Another potential avenue for treating stroke is via anti-inflammatory interventions 
(Perera et al., 2006).  Treatments are typically aimed at down-regulating immune cells 
and inhibiting enzymes responsible for generating toxic mediators.  However, it is 
unlikely that a specific inhibitor of a certain site will have a detectable effect, since the 
inflammatory response is such a complex, overlapping process (del Zoppo, Becker, & 
Hallenbeck, 2001; Hallenbeck & Frerichs, 1993).  Other interventions have focused on 
drugs that reduce ROS levels.  For example, a free radical-trapping agent named “NXY-
059” has shown some effectiveness in treating ischemic stroke (Lees et al., 2006). 
There are many other prospective interventions (e.g., use of growth factors, cell-
based therapies, electromagnetic stimulation) being tested to improve functional 
restoration after stroke (see Cramer, 2008b for a review of several therapies), but the 
majority of them will likely take years before their efficacy is demonstrated, will be very 
expensive, will have numerous side effects, and may never get through clinical trials.   
 
Polyphenols as a Treatment 
Polyphenols, particularly flavonoids, have vasoprotective and antithrombotic 
qualities that can aid in recovery following stroke (Bravo, 1998; Panickar & Anderson, 
2011).  As aforementioned, they are also potent antioxidants, reduce inflammation, 
protect against excitotoxicity, regulate apoptosis, alter hemodynamics, and have metal 
chelating properties.  Furthermore, it is possible that there is relatively large brain 
bioavailability of polyphenols after stroke, since ischemia can compromise the blood-
brain barrier (Borlongan et al., 2004; Brown & Davis, 2002; Latour, Kang, Ezzeddine, 
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Chalela, & Warach, 2004; Sandoval & Witt, 2008).  Additionally, by treating 
hypertension (Aviram & Dornfeld, 2001), atherosclerosis (de Nigris et al., 2005), 
diabetes (T. Huang et al., 2005), hyperlipidemia (Aviram et al., 2000), and coronary heart 
disease (Sumner et al., 2005), polyphenols have a role not only in improving recovery 
following stroke, but preventing the event altogether. 
Although no known study has assessed the effects of PPs following stroke in a 
clinical population, a few studies have examined the effects in animal models.  For 
example, one study demonstrated that a maternal diet of pomegranate juice protects 
newborn mouse pups from a prolonged ischemic injury (Loren et al., 2005).  The juice 
not only diminished caspase-3 activation (a protein involved in apoptosis) by 84%, but 
also decreased tissue loss by over 50%.  A follow up study replicated their previous 
findings, showing that pomegranate juice administered to mothers is neuroprotective to 
their offspring (West et al., 2007).  Other studies have shown that pomegranate extract 
prevents DNA damage and improves memory in rats subjected to cerebral ischemia 
(Ahmed, El Morsy, & Ahmed, 2014; Sarkaki & Rezaiei, 2013).  The protective influence 
of consumption of PPs against stroke likely also applies to humans, since increased fruit 
and vegetable intake in general is associated with decreased risk of ischemic stroke in 
both men and women (Gillman et al., 1995; Joshipura et al., 1999; Keli, Hertog, Feskens, 
& Kromhout, 1996). 
The ability of PPs to tackle chronic inflammation, oxidative stress, and other 
deleterious processes in a global, multi-approach manner makes them an exciting 
prospect for treating stroke.  Furthermore, they are very inexpensive, have no side effects 
in the majority of the population, have few contraindications, and have been shown to be 
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effective in numerous disease states.  
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CHAPTER THREE 
METHODS 
 
Subjects 
Participants were 16 adults who experienced an ischemic stroke and were 
admitted to the rehabilitation program at Loma Linda University East Campus Hospital 
(LLUECH) for inpatient care.  Half of the participants were randomly assigned to receive 
a PP supplement (n = 8) and the other half received a placebo (n = 8).  The treatment 
assignment was predetermined and known only by the pharmacy coordinator (Desiree 
Wallace, Pharm.D., R.Ph), who was not directly involved in patient care.  All other 
clinical staff remained blind to the treatment group, as were the patients.  Recruitment 
extended from June 2015 through March 2016.  During that 10-month interval, 183 
patients were admitted to LLUECH due to stroke.  Each admit was screened for potential 
study eligibility, and the resident physician (i.e., Paolo Jorge, M.D.) involved in the 
screening/consenting process met with 48 patients to further assess their eligibility.  
Twenty two patients (12% of total admits) met all inclusion criteria (see criteria below).  
Of these 22 patients, 6 declined to participate, with the main stated reason being that they 
did not want to take any additional medication.  The remaining 16 patients (9% of total 
admits) agreed to participate and signed informed consent documentation.  Two 
participants (1 in each treatment group) did not complete post-treatment testing (see 
Subject Inclusion Approach subsection below for more details), and were thus excluded 
from the final analyses.  Figure 5 is a flow diagram of the screening/recruitment process 
and distribution across the two study arms.  
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Analyzed  (n = 7) 
 
   
Assessed for eligibility (n = 183) 
Excluded  (n = 167) 
  Not meeting inclusion 
criteria (n = 161) 
  Declined to participate 
(n = 6) 
Analyzed  (n = 7) 
 
Received follow-up testing  
(n = 7) 
  Discontinued intervention 
due to psychotic episode  
   (n = 1) 
Allocated to POMx intervention  
(n = 8) 
 Received allocated 
intervention (n = 8) 
Received follow-up testing  
(n = 7) 
   Discontinued intervention 
due to not wanting to take 
any more medications  
     (n = 1) 
Allocated to placebo control  
(n = 8) 
 Received allocated 
intervention (n = 8) 
Allocation 
Randomized (n = 16) 
Figure 5.  Flow diagram of subject progress through study phases.  Figure adapted from 
CONSORT; http://www.consort-statement.org/consort-statement/flow-diagram 
 
Enrollment 
Follow-Up 
Analysis 
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Randomization 
Random assignment to treatment group is the gold standard for allocation 
methodology, since it eliminates sampling bias and allows for causal inferences to be 
made (Little et al., 2012).  We used a form of restricted randomization called “permuted-
block randomization” to balance group sizes given the relatively small sample size.  A 
block size of 4 and allocation ratio of 1:1 was chosen to ensure balanced groups.  Thus, 
every group of 4 subjects had an equal number of individuals receiving pomegranate or 
placebo supplements to ensure that the treatment groups would be roughly equal if we 
were unable to attain the desired sample size (originally set at 28).  As aforementioned, 
our allocation concealment method (i.e., our procedure for ensuring that treatment 
allocation was kept masked) was a technique known as “pharmacy-controlled 
randomization,” meaning that only the lead pharmacist knew the specific treatment each 
subject received. 
 
 
Inclusion/Exclusion Criteria 
Patients were included in the sample if they (1) were admitted to LLUECH 
immediately following medical stabilization for an ischemic stroke, (2) were between 18-
89 years old, (3) spoke English fluently, (4) were not globally aphasic, (5) were not 
currently taking warfarin (Coumadin), (6) had not suffered an intracerebral hemorrhage 
in the past 6 months, (7) had not undergone neurosurgery in the past month, (8) were not 
pregnant, (9) had at least 6 years of education, (10) had no history of traumatic brain 
injury, (11) had no history of neurologic condition with known cognitive impact (e.g., 
dementia), (12) did not have active renal or liver disease, (13) had no history of allergy to 
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pomegranate products, (14) were less than one month post-stroke, (15) had an estimated 
length of hospital stay that exceeded the study timeline, and (16) attained a score of at 
least 18/30 on the Mini-Mental State Examination – Second Edition (MMSE-2).  See 
Appendix D for the checklist the resident physician used to assess whether patients met 
the inclusion criteria. 
 
 
Procedures 
 Dr. Jorge, under the supervision of an attending physician (Mary Kim, M.D.) 
screened newly admitted LLUECH patients for individuals who met study criteria.  The 
physician met with patients who appeared to be potential candidates to provide 
information regarding the study, ensure they met inclusion criteria (including 
administering the MMSE-2), review informed consent documentation, and ask if they 
would like to participate.  The physician then filed the signed informed consent 
documents (see Appendix A, B, and C), provided authorization to nursing and pharmacy, 
and documented the interaction in the patient’s medical record (see Appendix E and F for 
physician work flow and initial patient visit script). 
 A trained psychology doctoral student (Jeff Murray) under the supervision of a 
board-certified neuropsychologist (Travis Fogel, Ph.D., ABPP-CN) administered a brief 
neuropsychological testing battery to newly consented patients to establish pretreatment 
baseline cognitive abilities (see Appendix G for neuropsychology procedure).  Nursing 
staff subsequently administered pomegranate or placebo capsules twice per day (9am and 
9pm) for the following week, for a total of 14 doses (see Appendix H for the nursing staff 
information sheet).  A post-treatment neuropsychological evaluation was conducted at the 
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end of the treatment week (refer to Table 1 for a depiction of the timeline and sequence 
of procedures).  Onsite healthcare staff monitored treatment compliance and adverse 
events.  All procedures were conducted in accordance with the Loma Linda University 
Institutional Review Board (IRB) guidelines and approval. 
 
Table 1. Timeline and sequence of procedures. 
 
Day 1 Days 2-8 Day 9 
 
Informed Consent 
 
Pomegranate Supplements 
or Placebo Taken Orally 
Twice Per Day (14 total 
doses) 
 
Neuropsychological 
Baseline Testing 
 
Neuropsychological Post-
Treatment Testing 
 
 
Treatment was delivered within the time window for spontaneous recovery (i.e., 
during the second epoch), which has been referred to as the “golden period” for initiating 
restorative therapies following stroke (Cramer, 2008a).  Regarding the treatment timeline, 
many studies have administered PPs for a long period of time, as much as 1 year in 
animal studies and 1.5 months in clinical populations.  The typical length of stay for 
inpatients at LLUECH has traditionally been under three weeks, thus limiting the 
treatment duration.  Although our original plan was to deliver treatment for two weeks, 
we opted to change to a one-week treatment protocol after 5 months of very low subject 
recruitment due to the combination of a low census and short hospital stays.  We also did 
this to increase the probability that each participant would receive the same duration of 
treatment, rather than risk subjects discharging prior to the completion of the treatment 
protocol. 
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 Prior pomegranate studies have found effects following relatively short treatment 
protocols.  For example, the aforementioned study that administered pomegranate extract 
after ischemic injury in rats only administered the treatment for two weeks (Sarkaki & 
Rezaiei, 2013).  Additionally, a recent clinical pilot study showed that one POMx pill per 
day for two weeks decreased oxidative stress (Hayek, Rosenblat, Volkova, Attias, & 
Mahamid, 2014).  Other studies also utilized a two-week protocol (at a single dose per 
day) and found positive effects of pomegranate treatment (Ahmed et al., 2014; Al-
Jarallah et al., 2013; Asgary, Keshvari, Sahebkar, Hashemi, & Rafieian-Kopaei, 2013; 
Asgary et al., 2014).  One study showed that even one dose benefited diabetic patients 
(Banihani et al., 2014).  Due to these positive findings following brief administration 
periods, we were optimistic that the protocol chosen for the current study (i.e., a total of 
14 doses) would be sufficient to observe effects. 
 
 
Setting 
 The rehabilitation program at LLUECH is a CARF (Commission on Accreditation 
of Rehabilitation Facilities) accredited Stroke Specialty Program.  According to CARF 
International’s website (http://www.carf.org/providerProfile.aspx?cid=14678), a 
Comprehensive Integrated Inpatient Rehabilitation Program must provide coordinated 
and integrated medical and rehabilitation services 24 hours a day and endorse the active 
participation and preferences of the person served throughout the entire program.  There 
must be collaboration with interdisciplinary team members, and individual resource 
needs and predicted outcomes of the person served must drive the appropriate use of the 
rehabilitation continuum of services.  Patients typically get a number of rehabilitative 
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services from professionals in diverse disciplines, such as physical therapy, occupational 
therapy, therapeutic recreation, and speech therapy.  They also have daily interactions 
with medical and nursing staff, frequent meetings with a social worker who coordinates 
discharge planning, the option to meet with chaplain, and access to specialists as needed 
(e.g., neuropsychology, psychiatry, ophthalmology).  Patients are often transferred to 
LLUECH following stabilization at Loma Linda University Medical Center, which is 
recognized as a Certified Stroke Center by The Joint Commission.  
 
 
Pomegranate Polyphenol Treatment 
We administered two POMx or placebo capsules (POM Wonderful, CA, USA) to 
participants per day, one in the morning and one in the evening.  Each POMx capsule 
contained 1g of a concentrated blend of polyphenols derived from 240mL of 
pomegranate juice (approximately 375mg punicalagins, 93mg anthocyanins, 29mg 
ellagic acid, and 100mg of other tannins).  We chose to use supplements, as opposed to 
pomegranate juice, because they do not contain sugar (so we could administer them to 
diabetic patients), are easier to swallow (since many stroke survivors experience 
dysphagia), and do not have the tart taste some individuals dislike.  Additionally, POMx 
supplements have been shown to have similar levels of polyphenols as compared with 
pomegranate juice (Seeram, Zhang, et al., 2008).  Administering two capsules per day is 
approximately the equivalent of two cups of pomegranate juice, and has been shown to 
be a safe and effective dose in other human studies (Balbir-Gurman et al., 2011; Heber et 
al., 2007; Paller et al., 2012; Seeram, Zhang, et al., 2008).  Furthermore, POMx 
supplements have Generally Recognized as Safe (GRAS) status by the U.S. Food and 
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Drug Administration.  Placebo capsules did not contain pomegranate ingredients.  The 
nursing staff at LLUECH administered the capsules along with the participant’s other 
medications and documented that each patient took each dose.  POM Wonderful provided 
all placebo capsules used for this study (they were re-purposed from a previous study), 
and we purchased POMx capsules directly from the company.  All staff involved in the 
study denied any conflicting interest with POM Wonderful, and the company did not 
provide any financial support for the project.  Although many other companies sell 
pomegranate extract products for much cheaper (see Vitacost.com, as one example), 
POM Wonderful’s products have received the most attention from the scientific 
community.  We administered a questionnaire regarding pre-admittance diet to 
participants to attain an estimate of polyphenol intake prior to being admitted to the 
hospital. 
 
 
Risks and Potential Drug Interactions 
 As aforementioned (see Chapter 2), recent data suggest that pomegranate products 
have an effect on hemodynamic forces, likely reducing platelet activation (Mattiello et 
al., 2009).  Although these effects lead to cardiovascular health benefits, the decreased 
risk of blood clots associated with the inhibition of platelet function could potentially 
result in an increased risk of bleeding.  Although there have been no known publications 
regarding adverse effects based on decreased platelet function, and there were no adverse 
events reported from our recent study assessing the effects of POMx in a high-risk 
cardiac surgery population (Ropacki et al., 2013), we opted to exclude patients who had 
suffered a hemorrhagic stroke or had undergone neurosurgery in the month prior to 
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hospital admission from the current study as an added precaution.  For similar reasons, 
we also excluded patients who had an intracerebral hemorrhage in the past 6 months or 
neurosurgery in the past month. 
Some authors have expressed a potential for polyphenol-drug interactions, 
although only a few case studies have been reported.  Specifically, pomegranate products 
have been alleged to have a modulatory effect on response to warfarin (Coumadin), an 
anticoagulation drug (Komperda, 2009).  One recent review article examined the 
available literature regarding the potential interaction between warfarin and fruit products 
and concluded that, although evidence is scarce, clinicians are encouraged to inquire 
about the consumption of pomegranate juice when determining potential causes of 
international normalized ratio (INR; a measure of clotting tendency of blood) instability 
(Norwood, Parke, & Rappa, 2014).  Another review article stated that, although 
pharmacokinetic data from in vitro and animal studies suggest the possibility of 
pomegranate intake affecting subsets of cytochromes P450 (CYP3A4/CYP2C9; enzymes 
involved in drug metabolism), current evidence suggests that patients can safely consume 
pomegranate products along with drugs that are substrates for CYP3A4 and CYP2C9 
(Srinivas, 2013).  However, due to the potential for an interaction between warfarin and 
POMx, we excluded patients being administered warfarin from the study. 
 
Neuropsychological Testing 
We administered a battery of widely used neuropsychological measures at two 
time-points (pre- and post-treatment).  The measures included paper and pencil types of 
tests that assessed a breadth of cognitive and psychological domains (refer to Table 2 for 
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a list of test by domain and administration time-point).  Although minor practice effects 
were expected on post-treatment (i.e., Time 2) performance, each group received the 
same protocol, so these effects have likely been averaged out.  Furthermore, alternate 
versions of measures were used when available (e.g., MMSE-2 and RBANS) to minimize 
such effects.  Each evaluation took approximately one hour to complete.  Although the 
data reported in the Results section are in their raw form unless otherwise specified, we 
also compared performance after norming the data based on normative data that were 
either included in a measure’s manual or were commonly used among 
neuropsychologists to determine if standardization altered the results.  Most normative 
data were age matched and some were also education or gender matched (see Table 3 for 
the characteristics of the normative data used for each measure).  We reported RBANS 
data as standard scores in the Results section because the 6 RBANS Indexes are not 
available in raw form since they are composites of subtests (see the Statistical Analysis 
section below for more details). 
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Table 2. List of neuropsychological measure by domain and time-point. 
 
Neuropsychological Measure Domain Assessed Time-point 
   
Repeatable Battery for the Assessment 
of Neuropsychological Status 
(RBANS) 
 1 (Form A) 
&  
2 (Form B) 
          List Learning Immediate Memory  
          Story Memory Immediate Memory  
          Figure Copy Visuospatial/Constructional Ability  
          Line Orientation Visuospatial/Constructional Ability  
          Picture Naming Language  
          Semantic Fluency Language  
          Digit Span Attention  
          Coding Attention  
          List Recall Delayed Memory - Verbal  
          List Recognition Delayed Memory - Recognition  
          Story Recall Delayed Memory - Verbal  
          Figure Recall Delayed Memory - Visual  
 
Mini-Mental State Examination – 
Second Edition (MMSE-2) 
 
General Orientation and Gross 
Cognitive Functioning 
 
Prior to 
consent & 
time 2  
 
Test of Premorbid Functioning (TOPF) 
 
 
Estimate of Verbal Intelligence 
 
1 only 
 
Trail Making Test (TMT)  1 & 2 
          Part A Processing Speed  
          Part B Set Shifting, Executive Functioning  
 
Brief Test of Attention (BTA) Attention/Concentration 1 & 2 
 
Line Bisection Test Visuo-spatial Neglect 1 & 2 
 
Controlled Oral Word Association Test 
(COWAT) 
  
          FAS Verbal Fluency, Executive Functioning 1 & 2 
          Animals Semantic Fluency 1 & 2 
   
Pre- & Post-Test Rating 
 
Beck Depression Inventory – Second 
Edition (BDI-II) 
 
State-Trait Anxiety Inventory (STAI) 
 
Awareness of Functioning 
 
Depression 
 
 
Current and General Anxiety 
1 & 2 
 
1 & 2 
 
 
1 & 2 
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Table 3. Characteristics of normative data. 
 
Test Age Matched Education  
Matched 
Gender 
Matched 
Source 
RBANS ✓   Manual 
MMSE-2 ✓ ✓  Manual 
TOPF ✓   Manual 
TMT ✓ ✓ (for those age 55+)  (Tombaugh, 2004) 
BTA ✓   Manual 
COWAT ✓ ✓  (Tombaugh et al., 
1999) 
BDI-II    Manual 
STAI ✓  ✓ Manual 
 
 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 
The RBANS was the primary outcome measure used since it provides both a total 
scale score and scores for 5 different cognitive domains, is relatively brief (approximately 
20 minutes total), has alternate forms, and has been frequently used to assess cognitive 
ability following stroke.  Specifically, the test measures immediate memory (with list 
learning and story memory), visuospatial/constructional ability (with figure copy and line 
orientation), language (with picture naming and semantic fluency), attention (with digit 
span and coding), and delayed memory (with list recall, list recognition, story recall, and 
figure recall).  Scores from all subtests are aggregated into a total composite score.  Each 
subtest was scored according to the manual (Randolph, 2012). 
The validity and reliability of the RBANS has been established for various disease 
states, such as traumatic brain injury (McKay, Casey, Wertheimer, & Fichtenberg, 2007), 
dementia (Garcia, Leahy, Corradi, & Forchetti, 2008), end-stage liver disease (Mooney et 
al., 2007), schizophrenia (Wilk et al., 2002), and stroke (Larson et al., 2005; Larson et al., 
2003; Wilde, 2006), among other populations (Randolph, Tierney, Mohr, & Chase, 
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1998).  The test has strong psychometric properties that are similar to those of other 
commonly used neuropsychological measures, with the manual reporting average index 
reliabilities ranging from .75 (visuospatial/construction) to .93 (total index), and a test-
retest coefficient of .84 for the total scale (Randolph, 2012).  Other sources found similar 
reliability, with a test-retest stability coefficient of .77 for the total score in healthy 
participants (Wilk et al., 2002) and .81 in community dwelling older adults (Duff et al., 
2005).  Practice effects are minimal (Duff et al., 2005) and alternate-form comparison 
studies show total scale coefficients of .82 between forms A and B (Randolph, 2012).  
Intercorrelations among indexes range from .29 to .64.  Furthermore, the RBANS has 
been shown effective in distinguishing lesion location (both right versus left hemisphere 
and cortical versus sub-cortical) following acute ischemic stroke (Wilde, 2010). 
 
Mini-Mental State Examination – Second Edition (MMSE-2) 
 The MMSE-2 is a brief (about 10 minutes) screening tool that touches upon 
orientation to time and place, recall, attention/calculation, naming, repetition, 
comprehension, reading, writing, and drawing, with all the scores from these domains 
cumulating to a maximum of 30 points.  We administered alternate versions of this test at 
both testing time-points.  Although the first edition of the test is more widely used and 
has demonstrated acceptable validity in detecting impairment in stroke populations 
(Agrell & Dehlin, 2000), we chose to use the second edition because it has alternate 
forms and updated norms. 
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Test of Premorbid Functioning (TOPF) 
 The TOPF is a word pronunciation task that provides an estimate of educational 
achievement/general intellectual abilities.  It involves pronouncing words that become 
increasingly difficult and irregular, so that one would only be able to correctly pronounce 
the word if they had prior exposure to it or similar words.  It has been shown to be less 
susceptible to brain injury or disease processes than other measures (Green et al., 2008; 
see the Advanced Clinical Solutions manual), and thus can be conceptualized as an 
estimate of pre-stroke intelligence.  There are 70 items on the measure, although the test 
is discontinued following 5 consecutive errors.  The scorer tallies the total number correct 
out of the attempted items. 
 
Trail Making Test (TMT) 
 The TMT is one of the oldest and most widely used neuropsychological tools, and 
consists of two parts: Part A and Part B.  Part A involves drawing lines to connect a 
series of numbers in ascending order and requires visual scanning, psychomotor speed, 
attention/working memory, sequential processing, and the ability to maintain mental sets, 
as well as gross visuo-spatial and psychomotor functioning.  It is generally categorized 
under the processing speed or attention domains.  Part B is similar to Part A, but adds an 
alternating component, where the examinee must switch between a number and a letter, 
in sequential order.  This task requires the same abilities as in Part A, with the addition of 
the ability to rapidly switch mental set and attend to two thought processes.  Part B is 
typically classified as a task of executive functioning due to the set shifting and divided 
attention requirements.  On both Part A and Part B, the examiner calls attention to errors 
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on the spot and asks the examinee to correct the error.  The examiner notes how many 
seconds it took the examinee to reach the final number for Part A and Part B (providing 
two separate variables), as well as how many errors occurred on each part.  Time 
continues even if an error is committed.  The task is discontinued if a subject takes longer 
than 5 minutes.  In this situation, a score of “301” is assigned.  Fewer total seconds 
indicates better performance. 
 
Brief Test of Attention (BTA) 
 For the BTA, the examinee listens to a string of numbers and letters and must 
mentally tally (without the use of their fingers) how many numbers are in a particular 
trial.  They do this for 10 trials and then are given 10 additional trials with the task of 
tallying how many letters they hear.  The task increases in difficulty as the trials progress, 
and the entire test takes 5-10 minutes to complete.  The scorer adds the number of trials 
correct from all 20 trials to attain a total score. 
 
Line Bisection Test 
 The Line Bisection Test consists of 20 horizontal lines of varying length and 
proximity to the center (i.e., some are closer to the left or right sides of the page).  The 
examinee is asked to place a mark where they think the middle of each line is.  The scorer 
measures the degree of deviation from the center of each line and attains the absolute 
value of the average percentage of deviation across all 20 lines.  The scorer also attains 
the dominant direction of deviation (i.e., whether the examinee misses more to the left or 
to the right on average across the 20 lines).  The value of the largest deviation is imputed 
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for any omissions.  The test is a measure of sensory-perceptual functioning, specifically 
assessing hemispatial inattention or neglect, which is common following stroke. 
 
Controlled Oral Word Association Test (COWAT) 
 The COWAT is another very commonly used neuropsychological test and is a 
measure of controlled verbal fluency that is divided into two parts: phonemic and 
semantic fluency.  The phonemic fluency task involves the examinee naming as many 
words that begin with a certain letter of the alphabet as he or she can in 1 minute.  There 
are a few rules (i.e., no proper nouns, no numbers, and no words that have the same 
meaning and only differ by its suffix) and the task is repeated twice more with different 
letters each time.  The scorer tallies the total acceptable words from all 3 trials into one 
total score.  The number of perseverations or intrusions can also be tallied.  The semantic 
fluency task involves providing the examinee a category prompt.  For example, the 
examiner asks the examinee to name as many animals as he or she can in 1 minute.  Both 
parts are commonly included under the “language” sections of neuropsychological 
reports, and the phonemic fluency score is often also thought to tap into the executive 
functioning domain. 
 
Pre- and Post-Test Ratings 
 The examiner asked examinees to rate their concern regarding their cognitive 
ability both before and after engaging in testing.  They drew a line to denote where they 
fell on a continuum from “not concerned” to “very concerned,” and the scorer coded the 
mark from 1 to 11, respectively, based on a template.  Examinees were also asked to rate 
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how well they thought they performed on the testing, as well as how well they estimate 
they would have done if they engaged in the testing prior to their stroke.  These items 
were on a continuum from “extremely poorly” to “extremely well,” and were coded using 
the same scale (i.e., 1 to 11, respectively).  The four questions were meant to assess the 
subject’s level of insight, or awareness, regarding his or her difficulties both before and 
after testing.  The rating forms were adapted from forms created by Dr. Kyrstle Barrera 
and used with her permission. 
 
Beck Depression Inventory – Second Edition (BDI-II) 
 The BDI-II is a widely used self-report questionnaire of depressive symptoms.  
The examinee is asked to respond to 21 items by endorsing whether or not they 
experience symptoms of sadness, pessimism, past failure, loss of pleasure, guilty feelings, 
punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, 
agitation, loss of interest, indecisiveness, worthlessness, loss of energy, changes in 
sleeping pattern, irritability, changes in appetite, concentrating difficulty, tiredness or 
fatigue, and loss of interest in sex.  Examinees can also describe the degree of severity of 
each symptom, as each item ranges from 0-3.  The scorer adds the scores for each item to 
attain a total score, which is interpreted according to the following guidelines: 0-13 = 
minimal depression, 14-19 = mild depression, 20-28 = moderate depression, 29-63 = 
severe depression.  The attending physician and supervising neuropsychologist on the 
team were immediately made aware when a subject endorsed suicidal thoughts or wishes, 
which occurred for 2 subjects at baseline testing but none at post-treatment testing. 
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State-Trait Anxiety Inventory (STAI) 
 The STAI is a self-report inventory of anxiety symptoms.  The test consists of two 
parts: 20 questions that assess anxiety level at the time of the examination (i.e., state) and 
20 questions that assess the examinee’s general level of anxiety (i.e., trait).  Items include 
feeling at ease, feeling upset, feeling self-confident, feeling confused, feeling like a 
failure, feeling rested, and having disturbing thoughts, among others.  Examinees endorse 
1 of 4 options on a likert scale, from “not at all” to “very much so.” 
 
Data Collection and Storage 
Research data (e.g., informed consent documents and neuropsychological 
measures) were collected onsite by either a resident physician or psychology doctoral 
student involved in the study and were physically taken to LLUECH’s Department of 
Neuropsychology, where they were stored in hard copy format and kept in a locked 
office.  They were subsequently transported to the psychology department for long-term 
storage. 
 
 
Statistical Analysis 
 
We used Prism (version 6.0d for Mac OS X, GraphPad Software Inc.) for all 
analyses except for the MANOVA, which was conducted with SPSS (version 23).  We 
used the following website to attain Cohen’s d: http://www.uccs.edu/~lbecker/.  We 
corrected for multiple t-test comparisons with the Holm-Šídák test (similar to the 
Bonferroni correction, but slightly less stringent; Holm, 1979; Šidák, 1967).  Specifically, 
this method works by computing p-values for each comparison in the experiment, 
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ranking the values from smallest to largest, and sequentially assessing whether the value 
is less than alpha (.05) divided by the number of remaining comparisons (see 
http://www.graphpad.com/guides/prism/6/statistics/ for more information).  Only 
comparisons of interest were analyzed to limit the experiment-wise (i.e., type 1) error 
probability. 
All analyses were two-tailed, and error bars on figures represent ± standard 
deviation (SD) or confidence interval (CI), as specified.  A neuropsychology doctoral 
student (i.e., John Bellone) scored all tests and was blind until after all scoring was 
completed.  We did not perform any interim analyses.  We conducted all analyses using a 
complete case approach (i.e., excluding the 2 subjects without outcome data; see 
description below), unless otherwise specified.  Specific analyses for each aspect of the 
Results chapter are described below. 
 
Demographics and Stroke Characteristics 
Fisher’s exact test was used to assess differences in treatment group for 
categorical demographic and stroke characteristic variables, since this method is 
particularly appropriate for small sample sizes when the data are in the form of a 2x2 
contingency table (e.g., comparing whether there are differences in the number of males 
or females between the POMx and placebo groups).  We used the chi-squared test for 
categorical data that exceeded a 2x2 contingency table (e.g., assessing differences in the 
racial breakdown between treatment groups).  We used independent samples t tests for 
continuous data. 
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Baseline Test Results 
We evaluated baseline data with independent samples t-tests to assess if there 
were any pre-treatment differences in cognitive or emotional functioning.  We then 
attained an effect size (Cohen’s d) to assess the magnitude of differences for each 
parameter. 
 
Pre- and Post-Test Ratings 
We evaluated pre- and post-test rating data with independent samples t-tests. 
 
Aim 1: Assessing the Impact of PPs on Global Cognitive and/or Emotional 
Functioning 
 We used two-way mixed ANOVA to analyze global cognitive scores (i.e., 
RBANS total scale and MMSE-2) and measures of emotional functioning (i.e., BDI-II 
and STAI).  Treatment group (POMx and placebo) was the between-subjects factor and 
time (baseline and post-treatment testing) was the within-subjects factor.  We were 
mainly interested in whether there was a significant interaction of treatment and time 
(i.e., whether the POMx group showed greater improvement from baseline to post-
treatment testing than the placebo group).  RBANS data were age-normed based on the 
sample described in the manual (Randolph, 2012), and were analyzed as index scores 
(also referred to as standard scores), which have a mean of 100 and a standard deviation 
of 15.  Data for the other measures (i.e., MMSE-2, BDI-II, and STAI) were kept as raw 
scores.  We conducted Pearson product-moment correlation analyses between the TOPF 
and several outcome variables to determine the degree of co-variation.  We subsequently 
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used ANCOVA to assess whether the group difference on the RBANS total scale index 
score change would be altered when controlling for the TOPF variance. 
 
Aim 2: Assessing for Domain-Specific Response to Treatment 
 We calculated change scores by subtracting each subject’s pre-treatment score 
from his or her corresponding post-treatment score.  Positive scores indicate improved 
performance and negative scores indicate decline for all but four measures (i.e., TMT, 
Line Bisection Test, BDI-II, and STAI), which are the reverse.  We then used 
independent samples t-tests with these change scores to assess for group differences in 
change from pre- to post-treatment testing, and also assessed effect size (Cohen’s d) for 
each change score.  A one-way MANOVA was additionally conducted to determine if 
there was an effect of treatment on performance across the five RBANS indexes (i.e., 
whether the most affected cognitive domains were differentially benefited by PP intake).  
According to the RBANS manual, although it is permissible to interpret subtest scores, 
the index level is the primary level of interpretation since it has the highest degree of 
internal consistency and stability (Randolph, 2012).  We assessed retention memory by 
calculating a retention composite change score.  We arrived at this composite by creating 
z scores for each of the three retention change scores (i.e., list, story, and figure retention) 
based on the sample mean and standard deviation and averaging these z scores. 
 
Subject Inclusion Approach 
Eleven subjects (5 in the POMx group and 6 in the placebo group) completed the 
trial according to our protocol (i.e., 14 total doses).  One subject (assigned to the placebo 
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group) completed a full two-week treatment protocol (i.e., received 28 doses), which was 
prior to a protocol change from two weeks of treatment to one week due to unanticipated 
short lengths of stay.  Another subject (assigned to the POMx group) was also on track to 
complete a full two week protocol but was discharged early and thus only received a total 
of 18 doses.  A third subject (assigned to the POMx group) recruited after the protocol 
change also discharged early and only received 7 doses.  Two additional subjects were 
recruited and completed baseline testing but did not complete follow-up testing.  One of 
those subjects (assigned to the placebo group) voluntarily withdrew from the study 
reportedly because she “did not want any more chemicals in her body,” and the other 
subject (assigned to the POMx group) experienced auditory hallucinations and a 
psychiatry consultant recommended the discontinuation of treatment.  Notably, this latter 
subject began experiencing auditory hallucinations several days prior to POMx 
administration, but the psychiatrist recommended discontinuing it as a precaution since 
no other medications had recently been added to the patient’s regimen.  Also of note, a 
subject that was assigned to the placebo group also experienced hallucinations during his 
course of treatment. 
We followed the guidelines for statistical methods set by the CONSORT 
(Consolidated Standards of Reporting Trials) Statement (Schulz, Altman, & Moher, 
2010; more information available at www.consort-statement.org).  The CONSORT 
Statement (item 12a) suggests that investigators either use an “intention-to-treat” 
approach or a “complete case” approach.  An intention-to-treat approach includes each 
randomized subject in the final analysis, regardless of whether there were subjects who 
did not receive or adhere to the allocated treatment or withdrew from the study (the motto 
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is “once randomized, always analyzed”).  Although this method is the best way to fully 
preserve the benefit of randomization, it may be misleading if there were missing 
outcomes or non-adherence issues and has been criticized for being overly conservative.  
The complete case approach only includes subjects who have known outcomes in the 
final analysis.  Since we had a relatively small sample size and one subject from each 
treatment group missing outcome data, we chose to use a complete case approach and 
exclude those two subjects from the analyses. 
Another option we considered was to follow a strict “per protocol” approach 
(under the category of “modified intention-to-treat”), whereby the analysis would be 
restricted to subjects who fulfill the protocol exactly as written (e.g., no deviation in the 
number of doses received).  However, adhering to this criterion would exclude the three 
subjects who received either more or less than the 14 doses set in the updated protocol, as 
well as the two subjects who did not complete a post-treatment evaluation.  Furthermore, 
this method has been criticized for compromising the randomization process (Schulz et 
al., 2010) and is not recommended by the CONSORT Statement.  All decisions regarding 
the subject inclusion approach were made prior to the unmasking of treatment groups to 
prevent potential bias. 
 
 
IRB Approval Process 
 The process of going from project conception to subject recruitment was quite an 
extensive one.  The technical classification of the study was initially unclear, and there 
was uncertainty as to whether we would need to submit it for “full board” review and 
meet the additional requirements necessary for that process.  In speaking with 
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administrators from Research Affairs and IRB committee members, we were informed 
that, since the project was considered a clinical trial, we had to go through the Clinical 
Trials Center (CTC) before we could submit to the IRB.  We had several meetings with 
CTC staff, and they suggested many changes.  Several aspects of the original conceived 
project (e.g., incorporating blood draw pre- and post-treatment to assess polyphenol 
metabolites and inflammatory and oxidative stress markers, as well as getting lesion 
volume data from neurology and including non-stroke groups) were eliminated during 
this phase for numerous reasons, such as limited funds, lack of support from certain 
departments, and extra administrative requirements.   
Although we originally thought we could provide the supplements to patients 
ourselves (as was done in Dr. Hartman’s previous study), we discovered that since we 
were working with an inpatient population supplements would be considered 
“medication,” which meant we needed to have physicians submit the medication order, 
pharmacists dispense the supplements, and nurses administer them to patients.  Each of 
these layers added a level of complexity to the project, and we had to attain the approval 
of each individual and department that would be involved.  This led to further protocol 
modifications and substantial delays in initiating the study.  It would have also added 
significant expenses, but fortunately everyone was willing to work without compensation 
(other than eventual authorship), for which we were incredibly grateful.  The only 
exception to this was a minimal pharmacy fee to cover packaging expenses. 
 After finally receiving almost everyone’s approval (the exception was the nursing 
department, who the CTC said they would follow up with) we submitted the completed 
protocol to the CTC and received their approval (STAR #: 14109) to submit it to 
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Research Affairs for IRB review (now 6 months into the process).  The only other 
stipulation from the CTC was that we needed to register with ClinicalTrials.gov (NIH-
operated registry of national and international clinical trials), which we did (protocol ID: 
NCT02442804).  Research Affairs confirmed that the protocol would need to go “full 
board,” and we submitted 28 copies of our materials for consideration in the next 
meeting.  After several weeks, we received word of the committee’s decision to allow us 
to re-submit the protocol with several changes (e.g., tightening up the inclusion criteria 
and updating the informed consent document).  We made the requested changes and re-
submitted 28 copies in time for the next full board meeting.  They informed us that the 
study was conditionally approved, with the stipulation that we submit a letter of support 
from the nursing department, which took months to attain.  We eventually received and 
submitted this letter and received final IRB approval (IRB #: 5150122) the beginning of 
June (8 months into the process).  We recruited our first subject the following week. 
 
 
Advice for Junior Investigators 
 Despite the many details and set-backs of the project that were unanticipated and, 
to a large extent, unavoidable, there are many things that would have been helpful to have 
known at the outset, and several things that are common knowledge but worth re-stating.  
I would like to pass on the following information to those embarking on a dissertation or 
other large research project: 
 
 Find out all the IRB requirements by reviewing the university’s online 
information and speaking with administrators.  If you are planning a randomized 
controlled trial then you should familiarize yourself with the guidelines set in the 
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CONSORT Statement (www.consort-statement.org), and design the study with 
these guidelines in mind.  This process should be started as soon as possible. 
 Begin the project by conceiving of the ideal study, one that has a large sample 
size, several research arms, and everything that journal reviewers would want to 
see.  From there, it is essential to tailor the project with a focus on feasibility, and 
build in a substantial safety margin to allow for things to go wrong.  Although 
ambition is key to success, an overly ambitious design runs a high risk of failure.  
To further increase the chances of success, the design should be planned 
meticulously with every detail laid out, because a flaw or oversight at this stage 
could have drastic and uncorrectable consequences. 
 Be flexible and willing to make revisions on the fly.  Things will go wrong; 
collaborators may drop out or let you down, funding may be discontinued, and 
numerous administrative responsibilities will be added.  Following the above 
recommendation of leaving plenty of room for error and remaining flexible will 
provide a buffer against these inevitabilities.  Be sure to anticipate long delays in 
time-line estimations, and, above all, try to remain calm. 
 Be selective with the individuals you include in your research/clinical team.  
Building a responsible and reliable team is a prerequisite for success.  Once the 
team is assembled, make every detail of each person’s responsibilities explicitly 
clear, and frequently meet with everyone and send updates so each team member 
remains aware of the study’s progress. 
 Also be selective with the subjects you include in the study.  If you are conducting 
a randomized controlled trial you should strive to use an intention-to-treat 
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approach (see description above).  Thus, it is incredibly important that you ensure 
each potential recruit meets the strict, clear inclusion/exclusion criteria.  Do not 
assign someone a treatment allocation unless you are sure (within reason) that he 
or she meets those criteria, especially if you anticipate a small final sample size. 
 Consider arguing against suggested changes to the design that could negatively 
impact the study.  For example, we should have considered questioning the IRB 
committee’s suggestion to exclude patients on Coumadin, since there is 
insufficient evidence that pomegranate products modulate response to the 
medication and this criterion significantly limited the pool of potential recruits. 
 Keep a log/journal of all study details and progress.  Not only is this 
good/necessary scientific practice, but essential for being able to retrace your 
steps and demonstrate progress. 
 Complete all tasks that are your responsibility as soon as you can do them.  This 
is obvious but necessary to re-iterate.  There are so many details to attend to in a 
research study, and being the coordinator means that the majority of those details 
fall upon you, so make sure any delays are not because there is something you are 
procrastinating on.  Also, do not wait too long for others.  If someone hints that 
they might not want to be involved, or otherwise adds unnecessary delays, 
seriously consider excluding them or looking for alternatives.  
 Foster relationships with advisors and your research team so they want to help 
you and see you succeed.  The worst thing you can do is burn bridges or act in a 
way that fosters a negative reputation.  Work hard and be responsible, available, 
flexible, and respectful, and you will succeed.  
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CHAPTER FOUR 
RESULTS 
 
Demographics and Stroke Characteristics 
The mean age and education of the total sample was about 58 years (SD = 13.76) 
and 14 years (SD = 2.11), respectively, and there were no differences between treatment 
groups (see Table 4).  The sample was 71% male and the ethnicity was predominantly 
White (57%), with 29% being Black and 14% being Hispanic.  Every subject had a 
diagnosis of hypertension, 36% had diabetes mellitus, and 64% had dyslipidemia.  The 
majority reported a history of smoking (64%) and/or any alcohol use (71%).  On a health 
habits questionnaire filled out at the time of baseline testing, subjects on average 
indicated that their overall diet was “neutral” (on a scale from “not healthy” to “very 
healthy”), that they consumed fruits and vegetables every day (on a scale from “never” to 
“every day”), and that they exercised approximately once per week (on a scale from 
“never” to “every day”).  We did not observe any group differences on these parameters.  
However, the placebo group trended towards outperforming the POMx group on a 
measure of estimated verbal intelligence (i.e., the TOPF) given during the baseline 
assessment (p = .08). 
The average time from stroke onset to treatment initiation was about 13 days (SD 
= 4.68) and the average length of stay at LLUECH was about 19 days (SD = 6.61).  The 
placebo group spent more time at LLUECH than the POMx group (t12 = 2.64, p < .03), 
but the difference was not significant when correcting for multiple comparisons.  Lesion 
laterality (i.e., hemisphere affected) and location were determined by CT and/or MRI 
findings listed in the subjects’ medical records.  All subjects in the POMx group suffered 
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a stroke in the right hemisphere of their brain, and 5 out of the 7 subjects in the placebo 
group had a right hemisphere stroke.  The majority of subjects had a subcortical stroke 
(57%), with 14% having a stroke in their cortex and 29% having a mix of cortical and 
subcortical lesions.  None of the stroke characteristic variables were significantly 
different between treatment groups.  Refer to Table 5 for a detailed description of each 
subject’s neuroimaging findings and symptoms.  
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Table 4. Demographic data and stroke characteristics by treatment group. 
 
 POMx Placebo p-value 
 
Age in years (Mean ± SD) 
[range] 
 
 
56.29 (13.60) 
[39-73] 
 
58.86 (14.37) 
[40-77] 
 
.74a 
Years of education 
 
 
13.57 (1.81) 
[12-16] 
14.14 (2.48) 
[12-18] 
.63a 
Male/female 
 
5/2 5/2 1.00b 
Race (%)   .47c 
     White 43 71  
     Black 43 14  
     Hispanic 
 
14 14  
IQ estimate* 
 
84.57 (7.96) 
[76-100] 
95.00 (11.70) 
[85-115] 
.08a 
    
Lesion laterality, right/left 
 
7/0 5/2 .46b 
Lesion location (%)**   .22c 
     Cortical 29 0  
     Subcortical 57 57  
     Mix 
 
14 43  
Time from stroke onset to 
treatment initiation in days 
 
12.14 (2.41) 
[9-16] 
14.00 (6.30) 
[8-27] 
.48a 
Length of rehabilitation 
unit stay in days 
 
15.29 (4.27) 
[11-23] 
23.00 (6.46) 
[16-32] 
.02a,d 
Diabetes (%) 
 
14 57 .12b 
Dyslipidemia (%) 
 
57 71 1.00b 
Hypertension (%) 
 
100 100 1.00b 
SD = standard deviation 
a Independent samples t test 
b Fisher’s exact test 
c Chi-squared test 
d Not significant when correcting for multiple comparisons 
*IQ estimate is based on TOPF score. It is compared to normative data and is a standard score 
(mean = 100, SD = 15) 
**According to Physical Medicine and Rehabilitation History and Physical Note for each subject 
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Table 5. Imaging findings and symptoms for each subject. 
 
Subject # Imaging Findings* Symptoms* Treatment 
Group 
2 8mm R thalamic region (MCA) infarcts L hemiparesis, 
dysarthria, 
ataxia 
POMx 
3 R striatum and posterior R frontal lobe (MCA) infarct 
with probable thrombotic origin; complete occlusion of 
R ICA and high-grade stenosis of proximal L ICA; 
narrowing of the origins of the bilateral vertebral 
arteries 
L hemiparesis, 
left neglect, 
dysarthria 
Placebo 
5 R anterior pontine infarct (likely thrombotic); diffuse 
mid to moderate cerebral volume loss; intracranial 
atherosclerosis with narrowing of basilar artery 
L hemiparesis, 
dysarthria, 
dysphagia 
POMx 
6 R ICA stroke with R MCA distribution affected, 
involving R frontal and temporal lobes; complete 
occlusion of R ICA; also small posterior infarct 
L hemiparesis, 
dysarthria 
POMx 
7 Complete occlusion of R ICA and partial occlusion of 
mid M1 segment of R MCA with diminished flow to 
distal M1 and M2 segments, involving R temporal 
lobe, insular cortex, basal ganglia region, corona 
radiata, and anterior thalamus 
L hemiparesis, 
dysarthria, 
dysphagia 
Placebo 
8 L MCA stroke involving L putamen and mesial 
temporal lobe 
R hemiparesis, 
dysarthria 
Placebo 
9 Multiple infarcts in R PCA distribution involving 
exclusively the R occipital lobe; multiple old small 
lacunar infarcts in bilateral basal ganglia and thalami; 
etiology likely atheroembolic and hypertensive 
L neglect POMx 
10 R mid pons and posterior cortical aspect of L occipital 
lobe involvement 
L hemiparesis, 
double vision, 
hearing loss, 
mild dysarthria 
POMx 
11 R pons infarct (8x7mm); critical stenosis of R ICA (90-
99%);  
L hemiparesis, 
dysphagia, 
dysarthria; 
initial NIHSS 
was 6 
Placebo 
12 R PICA occlusion involving R cerebellum and medulla R ataxia, 
double vision, 
vertigo; NIHSS 
Placebo 
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was 5 
13 L central pons infarct; old R basal ganglia lacunar 
infarct; mild bilateral ICA plaque buildup 
R hemiparesis, 
dysphagia, 
dysarthria 
Placebo 
14 multiple foci of small infarcts in posterior limb of R 
internal capsule (subthalamic) 
L hemiparesis POMx 
15 R basal ganglia infarct extending to the body of the R 
caudate nucleus; etiology likely atheroembolic or 
cardioembolic; 50% stenosis in proximal R ICA 
L hemiparesis Placebo 
16 R posterior limb internal capsule infarcts extending 
16mm in length; smaller 5mm subacute infarct of L 
posterior limb internal capsule; mild white matter 
infarction or gliosis at the cerebrum 
L hemiparesis; 
NIHSS was 9 
POMx 
R = right; L = left; MCA = middle cerebral artery; ACA = anterior cerebral artery;  
ICA = internal carotid artery; PCA = posterior cerebral artery;  
PICA = posterior inferior cerebellar artery; NIHSS = National Institutes of Health Stroke Scale 
*According to Physical Medicine and Rehabilitation History and Physical Note for each subject 
Note: subjects 1 (Placebo) and 4 (POMx) were excluded since they are missing outcome data. 
 
 
 
Baseline Test Results 
 
 We compared baseline data on each outcome measure to determine whether there 
were any pre-treatment group differences.  The placebo group outperformed the POMx 
group on most tests, including each RBANS index (see Table 6).  The RBANS total scale 
score showed the greatest difference (t12 = 2.24, p < .05), but this difference was not 
significant when correcting for multiple comparisons.  The placebo group also reported 
fewer symptoms of depression and anxiety relative to the POMx group, but these 
differences were not significantly different.  The POMx group outperformed the placebo 
group on Animals (semantic fluency portion of the COWAT; t12 = 2.69, p < .02), but this 
difference did not reach significance when correcting for multiple comparisons. 
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Table 6. Baseline neuropsychological performance by group. 
 
 Mean (SD) p-value Cohen’s d* 
 POMx Placebo   
RBANS (Indexes)     
     Immediate Memory 81.00 (13.47) 88.71 (10.80) .26 .63 
     
Visuospatial/Constructional 
63.71 (9.32) 73.00 (10.20) .10 .95 
     Language 85.71 (6.40) 88.86 (6.20) .37 .50 
     Attention 62.71 (14.57) 78.29 (12.62) .05 1.14 
     Delayed Memory 81.00 (16.78) 85.86 (13.95) .57 .31 
     Total Scale 67.71 (10.63) 78.00 (5.89) .04a 1.20 
     
MMSE-2 23.00 (2.97) 25.14 (2.19) .16 .82 
     
TMT**     
     Part A 106.30 
(100.60) 
91.00 (77.97) .76 .17 
     Part B 195.70 
(102.40) 
215.30 
(107.30) 
.73 .19 
     
BTA 12.14 (4.06) 11.29 (5.99) .76 .17 
     
Line Bisection Test 9.13 (7.40) 7.37 (6.47) .65 .25 
     
COWAT     
     FAS 26.00 (8.56) 27.14 (3.13) .75 .18 
     Animals 16.29 (4.07) 11.57 (2.23) .02a 1.44 
     
BDI-II*** 14.86 (12.65) 10.14 (9.67) .45 .42 
     
STAI***     
     State 44.57 (18.12) 34.43 (10.29) .22 .69 
     Trait 41.43 (10.95) 32.86 (11.91) .19 .75 
RBANS = Repeatable Batter for the Assessment of Neuropsychological Status; 
MMSE-2 = Mini-Mental Status Examination – Second Edition; TMT = Trail Making Test; 
BTA = Brief Test of Attention; COWAT = Controlled Oral Word Association Test; 
BDI-II = Beck Depression Inventory – Second Edition; STAI = State-Trait Anxiety Inventory 
aNot statistically significant when correcting for multiple comparisons 
*general guidelines: .2 = small effect; .5 = medium effect; .8 = large effect 
**lower raw score indicates better performance 
***higher scores indicates more mood symptoms 
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Pre- and Post-Test Ratings 
Subjects in the placebo group were more concerned regarding their cognitive 
abilities than those in the POMx group prior to baseline testing (t12 = 3.57, p < .01).  The 
data also trended in the same direction regarding concern after baseline testing (p = .06).  
There were no differences in perceived performance on testing or estimated pre-stroke 
performance at this baseline assessment (although the latter approached significance, 
with the placebo group rating their hypothetical pre-stroke performance lower than the 
POMx group; p = .05).   
Subjects in the placebo group were again more concerned regarding their 
cognitive abilities than those in the POMx group prior to post-treatment testing (t12 = 
2.77, p < .02).  They were also more concerned regarding their cognitive abilities after 
post-treatment testing (t12 = 2.24, p < .05).  Additionally, the placebo group estimated 
their hypothetical pre-stroke performance to be lower than the POMx group at this post-
treatment testing time-point (t12 = 2.31, p < .04).  However, none of these differences 
were significant after correcting for multiple comparisons.  We did not observe any 
significant differences or trends in the change scores of the four ratings. 
 
 
Aim 1 
 
 The primary aim of the study was to assess whether treatment with PPs improved 
global cognitive and emotional functioning following stroke.  To accomplish this, we 
utilized the total scale index score on the RBANS, since this score incorporates the 
subjects’ performance on all five cognitive domains assessed.  Results of the two-way 
mixed ANOVA indicated that scores improved significantly over time (F1,12 = 5.35, p < 
.04).  We did not observe a significant main effect of treatment.  Although the POMx 
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group’s scores trended toward greater improvement over time relative to the placebo 
group’s scores (interaction of time and treatment, p = .14), we did not observe any 
significant differences (see Figure 6).  Figure 7 shows the RBANS total scale index score 
change for each subject.  The lower end of the 95% CI for the POMx group is above 
baseline, suggesting improvement, whereas the CI for the placebo group is within the 
baseline range, indicating a lack of improvement.   
We also assessed whether the results would differ if we only included subjects 
who had a subcortical stroke, since 4 in each group had this type of stroke.  The data 
trended in the same direction (i.e., the POMx group improving more than the placebo 
group) but there were no significant differences.  Although the TOPF (Test of Premorbid 
Functioning; IQ estimate) baseline standard score did not significantly correlate with the 
RBANS total scale index change score (see Figure 8), we conducted an ANCOVA using 
the TOPF score as the covariate since the groups trended toward different performance at 
baseline (p = .08).  This analysis showed that the POMx group improved significantly 
more than the placebo group (F1,11 = 5.37, p < .05; see Figure 9). 
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Figure 6. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 
total scale score A) over time and B) change (post-testing minus pre-testing score). 
 
 
 
Figure 7. RBANS total scale score change for each subject. 
Note: Subjects 13 (Placebo) and 16 (POMx) had a change score of 0, 
and subjects 1 (Placebo) and 4 (POMx) are missing outcome data. 
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Figure 8. Correlation between RBANS total scale score change  
and Test of Premorbid Functioning (TOPF) baseline score. 
 
 
 
 
 
Figure 9. RBANS total scale score change by group with TOPF  
baseline score as a covariate. 
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We also examined MMSE-2 score changes from pre- to post-treatment since the 
MMSE-2 is a widely used screening measure of global cognitive functioning, but found 
no significant difference (see Figure 10). 
 
 
 
 
Figure 10. Mini-Mental State Examination-2 (MMSE-2) score A) over time and B) change. 
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per protocol approaches (described in Chapter 3), just to ensure they did not lead to 
different findings, and observed the same trends as the complete case approach. 
 
 
 
Figure 11. Beck Depression Inventory-II (BDI-II) score A) over time and B) change. 
 
 
 
 
Figure 12. STAI score over time by group. 
 
 
Pre-treatment Post-treatment
0
5
10
15
20
25
30
35
R
a
w
 S
c
o
re
  
±
 S
D
BDI-II
POMx
Placebo
POMx Placebo
-30
-20
-10
0
10
20
BDI-II
R
a
w
 S
c
o
re
 C
h
a
n
g
e
 ±
 9
5
%
 C
I
Improved 
compared 
to baseline
Impaired 
compared 
to baseline
A) B)
Pre-treatment Post-treatment
0
10
20
30
40
50
60
70
R
a
w
 S
c
o
re
  
±
 S
D
STAI - State
Pre-treatment Post-treatment
STAI - Trait
POMx
Placebo
 70 
 
 
Figure 13. STAI change score by group. 
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story, and figure retention), although the POMx group trended toward better performance 
(p = .09). 
We then examined other measures (refer to Table 7) and found that the BTA 
(Brief Test of Attention) showed the largest improvement in the POMx group compared 
to the placebo group (t12 = 2.99, p < .02; see Figure 15).  However, after correcting for 
multiple comparisons, this difference was not significant.  Based on this finding, we 
tested the change in the Digit Span subtest of the RBANS (part of the Attention Index), 
since it is widely thought to be a measure of simple attention, but did not find a 
significant group difference.   
We observed the second largest change from pre- to post-treatment testing on the 
Animals portion of the COWAT, but it was in the opposite direction of the hypothesized 
effect, with the placebo group improving more than the POMx group in their ability to 
rapidly name animals (t12 = 2.52, p < .03; see Figure 16); they named approximately 3 
more animals on average than at their baseline testing, compared to the POMx group that 
named about the same number of animals as their prior performance.  This difference was 
not significant when correcting for multiple comparisons.  The finding led us to test for 
potential differences on the Semantic Fluency subtest of the RBANS (part of the 
Language Index), since it assesses the same domain (i.e., involves naming fruits and 
vegetables at baseline testing and naming animals found in a zoo at post-treatment 
testing).  No significant differences were found but there was a trend in the opposite 
direction, with the POMx group improving more than the placebo group (p = .10; see 
Figure 17). 
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As with Aim 1, all reported analyses and figures were done using the complete 
case approach.  However, we repeated all Aim 2 analyses using intention-to-treat (with 
the baseline observation carried forward imputation method for the 2 subjects with 
missing outcome data) and per protocol approaches, just to ensure they did not lead to 
drastically different findings, and observed the same trends as the complete case 
approach.  Furthermore, as mentioned in the Neuropsychological Testing section of 
Chapter 3, we also compared performance after norming the data to determine if 
standardization altered the results, and found that the two methods (i.e., using raw data 
versus standardizing the data) produced comparable results. 
 
 
 
Figure 14. RBANS index change score for each domain by group. 
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Figure 15. Brief Test of Attention raw score change. 
 
 
 
 
 
 
 
Figure 16. Animals (semantic fluency part of the COWAT)  
raw score change. 
 
 
 
POMx Placebo
-5
0
5
10
R
a
w
 S
c
o
re
 C
h
a
n
g
e
 ±
 9
5
%
 C
I
BTA
Improved 
compared 
to baseline
Impaired 
compared 
to baseline
POMx Placebo
-5
0
5
10
R
a
w
 S
c
o
re
 C
h
a
n
g
e
 ±
 9
5
%
 C
I
Animals (COWAT)
Improved 
compared 
to baseline
Impaired 
compared 
to baseline
 74 
 
 
Figure 17. RBANS Semantic Fluency subtest score change.  
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Table 7. Change scores for cognitive and emotional outcome measures by group. 
 Mean (SD) p-value Cohen’s d* 
 POMx Placebo   
RBANS (Indexes)     
     Immediate Memory 8.57 (13.24) 3.57 (14.32) .51 .36 
     
Visuospatial/Constructional 
4.43 (13.34) -6.14 (7.34) .09 .98 
     Language 6.86 (5.40) 1.29 (6.47) .11 .93 
     Attention 4.86 (5.96) 3.43 (9.36) .74 .18 
     Delayed Memory 2.43 (9.47) 1.71 (10.86) .90 .07 
     Total Scale 6.86 (6.52) 1.29 (6.65) .14 .85 
     
MMSE-2 0.83 (2.48) 0.43 (2.64) .78 .16 
     
TMT**     
     Part A -18.14 (18.80) -19.86 
(33.35) 
.91 .06 
     Part B -20.00 (21.03) -39.00 
(39.64) 
.28 .60 
     
BTA 3.29 (1.38) 0.14 (2.41) .01a 1.60 
     
Line Bisection Test -0.91 (3.79) -3.71 (4.69) .24 .66 
     
COWAT     
     FAS 1.29 (2.43) 2.14 (3.67) .62 .27 
     Animals -0.14 (2.19) 3.14 (2.67) .03a 1.34 
     
BDI-II*** 0.14 (9.58) -3.86 (9.48) .45 .42 
     
STAI***     
     State -5.86 (10.43) -2.86 (12.62) .64 .26 
     Trait -1.57 (7.87) -1.00 (9.17) .90 .07 
RBANS = Repeatable Batter for the Assessment of Neuropsychological Status; 
MMSE-2 = Mini-Mental Status Examination – Second Edition; TMT = Trail Making Test; 
BTA = Brief Test of Attention; COWAT = Controlled Oral Word Association Test; 
BDI-II = Beck Depression Inventory – Second Edition; STAI = State-Trait Anxiety Inventory 
*general guidelines: .2 = small effect; .5 = medium effect; .8 = large effect 
**lower raw score indicates better performance 
***higher scores indicates more mood symptoms 
aNot statistically significant when correcting for multiple comparisons 
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CHAPTER FIVE 
CONCLUSION 
 
Discussion/Implications of the Findings 
 
 In the present study, we recruited 16 subjects who recently suffered an ischemic 
stroke and tested their cognitive functioning and mood symptoms before and after one 
week of pomegranate supplement (i.e., POMx) or placebo intake.  Subjects were 
randomly assigned to treatment groups and both they and their clinical team were blind to 
the treatment allocation.  Few studies have assessed the effects of PPs on cognitive and 
emotional functioning, and no known clinical study has examined their efficacy in 
enhancing neuropsychological recovery following a stroke.  Overall, the results trended 
toward subtle improvements in cognitive abilities in pomegranate-treated subjects 
compared to placebo-controlled subjects, but no differences or trends were observed 
regarding emotional functioning. 
 Although our randomization protocol yielded groups that were demographically 
quite similar, it was surprising to observe that the groups differed at baseline (i.e., pre-
treatment) on a number of measures (albeit not significantly), including higher estimated 
intellectual functioning of the placebo group compared to the POMx group.  The placebo 
group also reported fewer mood symptoms at baseline testing.  This could have 
potentially improved our chances of finding effects of POMx since the POMx group had 
more room to improve, but it could have also hurt our chances since individuals with 
lower intellectual abilities may tend not to improve as much in general, or may have a 
floor effect on testing (i.e., perform below the limit of our instruments and thus preclude 
the observance of true differences). 
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 We observed several trends when comparing groups on post-treatment 
performance while accounting for pre-treatment performance.  The main outcome 
measure we used was the RBANS total scale score, which is robust since it incorporates 
scores from the five RBANS indexes.  The POMx group significantly improved over 
time while the placebo group did not, and these effects were likely driven by trends in the 
visuospatial/constructional and language domains, since these were more improved in the 
POMx group relative to the placebo group.  Furthermore, the POMx group improved 
significantly more than the placebo group when controlling for baseline intellectual 
functioning, as measured by the Test of Premorbid Functioning (TOPF).  These findings 
corroborate the results of other studies using pomegranate products to ameliorate 
cognitive deficits in clinical populations of various pathologies (Bookheimer et al., 2013; 
Ropacki et al., 2013).  However, it is important to note that both groups performed poorly 
relative to the age-matched normative sample (i.e., the sample the RBANS was normed 
on; post-treatment total scale score: POMx = 4th percentile, placebo = 6th percentile), 
which is consistent with other studies showing that cognitive deficits are prevalent 
following stroke (Hofgren et al., 2007; M. Patel et al., 2003). 
Outside of the RBANS, differences fell below the p < .05 level on two cognitive 
measures, although these differences were not significant when correcting for multiple 
comparisons with the Holm-Šídák method.  Furthermore, these differences were in 
disparate directions.  Specifically, the POMx group showed the largest improvement on 
the BTA (Brief Test of Attention), whereas the placebo group showed the largest 
improvement on rapid animal naming.  It is difficult to make any interpretive claims 
regarding these effects, especially because outcomes from similar measures did not 
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converge with either of the findings.  It is possible that the Animals finding is due to 
regression toward the mean, since the placebo group trended toward poorer performance 
than the POMx group on the baseline testing.  Additionally, there was another semantic 
memory task that also involved rapid animal naming, and the difference trended in the 
opposite direction (i.e., the POMx group outperforming the placebo group).  Regression 
toward the mean was likely not an explanation for the difference observed on the BTA 
since both groups were similar at baseline.  However, since these differences were not 
significant after correcting for multiple comparisons, they should be considered as only 
trends. 
Being that the present study is a pilot trial and that there is little guidance from the 
literature as to what to expect regarding the effects of PPs on cognitive and emotional 
functioning in a clinical population, the findings are meant to guide future research.  
Despite being substantially underpowered, we observed several interesting trends and 
differences in the data that suggest that a larger sample size or other design changes (see 
Limitations section below) may have uncovered larger effects. 
 
Limitations 
We acknowledge several limitations in the present study: 
 
1. The sample size was relatively small, with 16 total subjects recruited and 14 
analyzed.  This was meant as a pilot trial, since no known study has examined the 
neuropsychological effects following polyphenol administration in a clinical 
stroke population, and we expected to be somewhat underpowered.  Although 
recruitment was open for 10 months, the patient census was unusually low and 
there were many stroke patients who did not meet our strict inclusion criteria.  We 
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were more interested in carefully selecting appropriate candidates for recruitment 
and ending up with a relatively homogenous sample than recruiting as many 
subjects as possible.  This allowed us to limit many potential confounding factors 
(e.g., cognitive decline due to a neurodegenerative process). 
2. Many other studies using PPs had longer treatment durations than the one-week 
period in the present study.  We originally attempted a two-week treatment 
protocol (28 doses), but relatively short rehabilitation lengths of stay did not make 
that duration feasible, so we opted to change it to a one-week treatment protocol 
(14 doses).  It is likely that our chances of finding significant effects would have 
improved substantially with longer treatment periods. 
3. Many prior animal and human studies assessing the effectiveness of PPs in 
various disease states (e.g., AD, radiation exposure, cardiac surgery, stroke) had 
begun PP administration before insult, which may have primed the body to defend 
against the pathological effects after injury.  In the present study, it was not 
possible to begin treatment administration until after a stroke had occurred (days 
to weeks after the event).  Although others have seen behavioral effects when PPs 
were administered postischemic injury (Sarkaki & Rezaiei, 2013), and our 
treatment initiation was still well within the therapeutic window (Cramer, 2008a; 
Emsley et al., 2003), it is likely that our chances of finding differences would 
have been optimized if treatment was initiated before the insult. 
4. There was some heterogeneity in the sample, especially regarding stroke location.  
Although comparing post-treatment functioning to baseline functioning attenuates 
the relevance of inter-subject differences, and true randomization is the best way 
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to control for heterogeneity, it is possible that this could have led to variability in 
the domains affected by stroke, the recovery trajectory, and/or the response to PP 
administration. 
5. Our sample may not be considered generalizable to all people who have suffered 
a stroke, since this was a highly selected (i.e., long exclusion criteria list) sample 
of patients receiving intensive inpatient rehabilitation services, which likely 
contributed to their functional gains. 
 
Future Directions 
 The present findings lead to many more questions regarding the effects of 
pomegranate supplementation after stroke.  Since this study was the first to examine 
neuropsychological outcomes following pomegranate treatment in a clinical stroke 
population, replication studies are needed to ensure the validity of the present findings.  
Obvious improvements for these hypothetical future studies would be larger sample sizes 
with longer treatment durations (e.g., weeks to months) and later assessments (e.g., 1 year 
post-stroke).  Additionally, subsequent studies could use different doses of POMx or 
other pomegranate products, as well as other measures to test different behavioral 
constructs.  Jeff Murray, the psychology doctoral student who tested subjects in the 
present study, is currently examining another construct, FIM (Functional Independence 
Measure) scores, as part of his doctoral project.  The FIM system is routinely employed 
at LLUECH and other rehabilitation centers, and is used to assess a patient’s motor 
functioning/mobility, ability to engage in activities of daily living, social interaction, and 
problem solving ability, among other abilities.  Furthermore, the measure has been 
validated in an acute stroke population (Hsueh, Lin, Jeng, & Hsieh, 2002).  Jeff is 
 81 
currently in the process of comparing the FIM scores attained at post-treatment from 
LLUECH with their baseline scores to assess whether the POMx group improved in 
relation to the placebo group. 
There are several other avenues to explore.  For example, it would be extremely 
informative to assess various biomarkers, such as inflammation (e.g., via C-reactive 
protein, white blood cell count, TNF α, leukocyte count, or fibrinogen) and ROS (e.g., via 
8-isoprostane, lipid peroxide, nitric oxide/nitrite, superoxide dismutase, or 8-hydroxy-2-
deoxyguanosine), to better understand the potential mechanisms mediating any 
relationship between PP intake and improvements in cognitive/emotional functioning.  It 
would also be beneficial to test for pomegranate metabolites (e.g., via trolox equivalent 
antioxidative capacity or urolithin A-glucuronide) to confirm increased antioxidant 
concentrations in the pomegranate group (as was accomplished in Bookheimer et al., 
2013), especially since the precise bioavailability of PPs is still unclear.  Attaining lesion 
volume data (e.g., via MRI or CT scans) both before and after treatment would also help 
clarify the neurological effects of PPs. 
Another option is to recruit individuals who are at substantial risk for suffering a 
stroke (e.g., older adults with hypertension, dyslipidemia, and diabetes mellitus) and 
assign them to either take pomegranate products or a placebo.  This could help to 
improve our understanding of the effects of PPs on cerebrovascular risk factors, as well 
as aid in discovering whether PPs are protective for individuals who later go on to have a 
stroke.  This design would have the added benefit of better modeling most animal studies, 
where treatment is usually initiated prior to injury/stroke. 
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Concluding Remarks 
Given the growing popularity of dietary manipulations and increased polyphenol 
intake, it is important to ensure the safety of these agents and identify potential 
therapeutic approaches.  We hope the present study sparks more research that improves 
our understanding of how dietary interventions may be used to enhance cognitive 
recovery after a very common, often debilitating, cerebrovascular event, as well as 
promotes healthy lifestyle changes in those who have cerebrovascular risk factors.  We 
also hope that subsequent studies will continue to assess the effectiveness of polyphenols 
and other dietary interventions among stroke survivors, potentially introducing 
inexpensive and safe treatments that lead to improved cognitive functioning, better 
quality of life, and a reduced financial burden on hospitals and communities. 
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APPENDIX A 
 
INFORMED CONSENT DOCUMENT 
 
 
 
 
 
 
 
 
 
TITLE: THE EFFECTS OF POMEGRANATE 
POLYPHENOLS ON NEUROPSYCHOLOGICAL 
FUNCTIONING FOLLOWING ISCHEMIC 
STROKE: A PILOT STUDY 
SPONSOR:   Department Funded 
PRINCIPAL 
INVESTIGATOR: Richard Hartman, Ph.D. 
 Loma Linda University 
 Department of Psychology 
 School of Behavior Health 
 Loma Linda, CA 92350 
 Telephone Number: [omitted] 
   
1. WHY ARE WE DOING THIS STUDY? 
 
We want to conduct this study to examine whether dietary supplementation with an 
antioxidant (pomegranate extract) can help promote healthy cognitive functioning 
(i.e., thinking ability, such as memory or attention) as a component of recovery after 
stroke. 
 
You are invited to participate in this research study because you are a patient at the 
Rehabilitation Institute, recently suffered a stroke, and meet our criteria for 
involvement.  
 
Approximately 28 subjects will participate in this study, all of which will be subjects 
at Loma Linda University (LLU). 
 
2. HOW WILL YOU BE INVOLVED? 
 
Participation in this study involves the following: 
 
 You will be assigned to one of the groups by chance, using something like the flip 
of a coin, to determine if you will take the antioxidant capsule or a placebo 
School of Behavioral Health 
Department of Psychology 
11130 Anderson Street 
Loma Linda, California 
(909) 558-7116 
Fax   (909) 558-0171 
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capsule (i.e., sugar pill).  Neither you, the clinician, nor your nursing staff will 
know which one you are receiving. 
 
 You will be given a series of tests of your cognitive skills and a few 
questionnaires of your mood and health habits.  One of these paper and pencil test 
sessions will be conducted right after you sign this informed consent agreement 
and the other will be given in approximately two weeks.  These tests should take 
less than one hour. Testing sessions will take place in a comfortable, quiet room 
in the hospital and you can take breaks as needed. 
 
 You will take 2 of the antioxidant capsules or 2 of the placebo capsules daily (one 
in the morning, one in the evening), which your nurse will give you along with 
your other medications, for 7 consecutive days during your stay at the hospital. 
 
If you agree to participate, you will be responsible for taking 2 brief sessions of cognitive 
testing and taking 2 extra supplements, one in the morning and one at night.  
 
3. WHAT ARE THE REASONABLY FORESEEABLE RISKS OR 
DISCOMFORTS YOU MIGHT HAVE? 
 
The committee at LLU that reviews human studies (Institutional Review Board) has 
determined that participating in this study exposes you to moderate risk. 
 
Although research suggests that allergic reactions to this antioxidant (or the fruit from 
which it is derived) and interactions with medications are uncommon, it is possible 
that some individuals may experience an allergic reaction or potential interactions 
between the supplement and the medicines they are taking. Also, it has been reported 
that this antioxidant has effects similar to aspirin and causes blood to clot less easily, 
which could increase the risk of bleeding.  To minimize these risks, anyone who has 
had a hemorrhagic stroke in the past 6 months, is taking Coumadin, or had brain 
surgery in the past month will not be considered for participation.  Please contact 
medical staff immediately if you notice any negative reactions that are likely 
associated with the study.  If such concerns arise during the course of your 
participation, you may be asked to discontinue your participation in the study.  If you 
have any concerns regarding your health that arise during the course of your 
participation, you should contact your doctor and nurse immediately. 
 
A possible discomfort resulting from your participation is temporary fatigue or 
frustration during the testing sessions.  To ease discomfort, you will be allowed to 
take breaks as needed.  Also, some participants may not like the taste of the 
antioxidant capsule or the placebo capsule.  Participants who are unable to tolerate the 
capsules may decline further participation in the study at any time.   
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4. WILL THERE BE ANY BENEFIT TO YOU OR OTHERS?  
 
It is possible that you may not receive any benefit from this study.  However, it is also 
possible that you may experience the benefits of the antioxidant supplement on 
overall health and/or cognitive functioning (that is, cognitive decline may be 
prevented or cognitive functioning may be improved). 
 
In addition, the information learned from this study will benefit others in the future.  
The results of this study may improve our understanding of cognitive functioning and 
factors that may affect cognitive functioning in persons who suffer a stroke, as well as 
in individuals who are at risk of having a stroke.  Results of this study may also 
improve our understanding of the role of diet on cognition and brain health, and lead 
to improved treatments for individuals with stroke and other related injuries.  The 
data collected from this study may also be published in scholarly journals. 
 
5. WHAT ARE YOUR RIGHTS AS A SUBJECT?  
 
Participation in this study is voluntary. Your decision whether or not to participate or 
withdraw at any time from the study will not affect your ongoing medical 
care/relationship with your health care team and will not involve any penalty or loss 
of benefits to which you are otherwise entitled.  You may get a second opinion about 
your decision to be in the study from another doctor at your own cost. 
 
Likewise, your study doctor or the study staff may withdraw you from the study for 
any reason without your agreement or may stop the study entirely. 
 
If you decide to withdraw from the study, you must notify the study doctor or study 
staff immediately at [omitted]. 
 
6. WILL YOU BE INFORMED OF SIGNIFICANT NEW FINDINGS?  
 
During the study, we may learn new things about the risks and benefits of the study.  
If such information might affect the willingness of individuals to be in the study, we 
will share this information with you.  Should your condition become worse, should 
side effects become severe, or should new scientific developments occur indicating 
that participating in this study is no longer in your best interest, then your study 
participation may be stopped and other options would be discussed.   
 
7. WHAT OTHER CHOICES DO YOU HAVE? 
 
You may consult a nutritionist if you have questions about any dietary or nutritional 
needs.  You may also request a neuropsychological evaluation if you have concerns 
regarding your cognitive functioning (i.e., thinking ability). 
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8. HOW WILL INFORMATION ABOUT YOU BE KEPT CONFIDENTIAL?  
 
Efforts will be made to keep your personal information confidential.  We cannot 
guarantee absolute confidentiality.  Your personal information may be disclosed if 
required by law.  You will not be identified by name in any publications describing 
the results of this study, nor in the government registration of this study.  Your 
personal information will be available only to those directly involved in the study or 
assessment procedures.  You will be given an identification number upon entry into 
the study that will be used to identify your test results.  Your neuropsychologist, who 
is a researcher in this study, may also use the results to best tailor your care while at 
the hospital.  All personal information will be kept in a locked office in the 
Department of Neuropsychology, and all test results will be kept on a password 
protected, secure computer in a separate locked office.  Your rights regarding 
permission to use your health information are described on the attached 
“Authorization for Use of Protected Health Information” form.  This informed 
consent form will also be input into your medical record. 
 
9. WHAT COSTS ARE INVOLVED? 
 
There is no cost to you for participating in this study.  The study/sponsor will pay for 
services, supplies, procedures, and care that are not a part of your routine medical 
care.  This includes the costs of the pomegranate supplements and pharmacy 
dispensing fees. 
 
You and/or your health insurance must pay for the services, supplies, procedures, and 
care required for routine medical care.  You will be responsible for any co-payments 
and/or deductibles as required by your insurance. 
 
10. WILL YOU BE PAID TO PARTICIPATE IN THIS STUDY? 
 
You will not be paid to participate in this research study.  However, you will not incur 
any additional costs as a result of your participation. 
 
11. WILL STUDY STAFF RECEIVE PAYMENT? 
  
The study is funded by the LLU Department of Psychology and study staff will not 
receive payment for their role in the study. 
 
12. WHO DO YOU CALL IF YOU ARE INJURED AS A RESULT OF BEING IN 
THIS STUDY?  
 
Your study doctors will be monitoring your condition throughout the study, and 
precautions will be taken to minimize the risks to you from participating.  If you are 
injured or become ill while taking part in this study, please do the following: 
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o Notify your doctor and nurse as soon as you can. 
 
Appropriate medical treatment will be made available to you.  However, you and 
your insurance company will be billed at the usual charge for the treatment of any 
research-related injuries, illnesses, or complications.  You might still be asked to pay 
whatever your insurance does not pay. 
 
Also, no funds have been set aside nor any plans made to compensate you for time 
lost for work, disability, pain, or other discomforts resulting from your participation 
in this research.  
 
By participating in the study, you do not give up any of your legal rights. 
13. WHO DO YOU CALL IF YOU HAVE QUESTIONS? 
If you wish to contact an impartial third party not associated with this study regarding 
any questions about your rights or to report a complaint you may have about the 
study, you may contact the Office of Patient Relations, Loma Linda University 
Medical Center, Loma Linda, CA 92354, phone (909) 558-4647, e-mail 
patientrelations@llu.edu for information and assistance. 
 
14.  SUBJECT’S STATEMENT OF CONSENT  
 
 I have read the contents of the consent form, which is in English, a language that I 
read and understand.  I have listened to the verbal explanation given by the 
investigator. 
 My questions concerning this study have been answered to my satisfaction. 
 I have received a copy of the California Experimental Subject’s Bill of Rights and 
have had these rights explained to me. 
 Signing this consent document does not waive my rights nor does it release the 
investigators, institution or sponsors from their responsibilities. 
 I may call Rich Hartman, Ph.D., during routine office hours at [omitted] if I have 
additional questions or concerns. 
 I understand that if I am enrolled in an inpatient study, my primary care physician 
may be notified of my participation for proper coordination of care. 
 I hereby give voluntary consent to participate in this study. 
 
I understand I will be given a copy of this consent form after signing it.  
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Signature of Subject  Printed Name of Subject 
  
AM / PM 
Date   Time 
 
 
If subject is physically unable to sign: 
 
Subject is unable to sign because ________________________________________.                                             
 
_______________________________________                                                  
Printed name of Subject 
 
I attest that the above named subject has indicated their consent to participate in this 
study. 
 
 
Signature of Witness  Printed Name of Witness 
 
 
 
 
AM / PM 
Date   Time 
 
 
15.  INVESTIGATOR’S STATEMENT  
 
I attest that the requirements for informed consent for the medical research project 
described in this form have been satisfied – that the subject has been provided with a 
copy of the California Experimental Subject’s Bill of Rights, that I have discussed the 
research project with the subject and that I have explained to him or her in non-technical 
terms all of the information contained in this informed consent form, including any risks 
and adverse reactions that may reasonably be expected to occur.  I further certify that I 
encouraged the subject to ask questions and that all questions asked were answered.  I 
understand that it is my responsibility to notify the subject’s primary care physician of 
study participation, as needed, for proper coordination of care.  I will provide the subject 
or the legally authorized representative with a signed and dated copy of this consent 
form. 
 
  
Signature of Investigator  Printed Name of Investigator 
 
 
 
 
AM / PM 
Date   Time 
 108 
APPENDIX B 
 
AUTHORIZATION FOR USE OF PROTECTED HEALTH INFORMATION 
 
 
INSTITUTIONAL REVIEW BOARD 
Authorization for Use of  
Protected Health Information (PHI) 
Per 45 CFR §164.508(b) 
RESEARCH PROTECTION PROGRAMS 
LOMA LINDA UNIVERSITY | Office of the Vice President of Research Affairs 
24887 Taylor Street, Suite 202 Loma Linda, CA 92350 
(909) 558-4531 (voice) / (909) 558-0131 (fax)/e-mail: irb@llu.edu 
 
TITLE OF STUDY: The Effects of Pomegranate Polyphenols on 
Neuropsychological Functioning Following 
Ischemic Stroke: A Pilot Study 
PRINCIPAL INVESTIGATOR: Richard Hartman, Ph.D. 
Others who will use, collect, or share 
PHI: 
 
Sub-investigators: 
Travis G. Fogel, Ph.D., ABPP 
Mary Kim, M.D. 
 
Students/Personnel: 
John A. Bellone, M.A. 
Jeffrey Murray, B.A. 
Paolo Jorge, M.D. 
 
The study named above may be performed only by using personal information relating to 
your health.  National and international data protection regulations give you the right to 
control the use of your medical information.  Therefore, by signing this form, you 
specifically authorize your medical information to be used or shared as described below. 
 
The following personal information, considered “Protected Health Information” (PHI) is 
needed to conduct this study and may include, but is not limited to: medical records and 
charts, results of blood tests, results of neuropsychological tests. 
 
The individual(s) listed above will use or share this PHI in the course of this study with 
the Institutional Review Board (IRB) and the Office of Research Affairs of Loma Linda 
University. 
 
The main reason for sharing this information is to be able to conduct the study as 
described earlier in the consent form.  In addition, it is shared to ensure that the study 
meets legal, institutional, and accreditation standards.  Information may also be shared to 
report adverse events or situations that may help prevent placing other individuals at risk.  
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All reasonable efforts will be used to protect the confidentiality of your PHI, which may 
be shared with others to support this study, to carry out their responsibilities, to conduct 
public health reporting and to comply with the law as applicable.  Those who receive the 
PHI may share with others if they are required by law, and they may share it with others 
who may not be required to follow national and international “protected health 
information” (PHI) regulations such as the federal privacy rule.  
 
Subject to any legal limitations, you have the right to access any protected health 
information created during this study.  You may request this information from the 
Principal Investigator named above but it will only become available after the study 
analyses are complete.   
 
-The authorization expires upon the conclusion of this research study. 
 
You may change your mind about this authorization at any time.  If this happens, you 
must withdraw your permission in writing. Beginning on the date you withdraw your 
permission, no new personal health information will be used for this study. However, 
study personnel may continue to use the health information that was provided before you 
withdrew your permission.  If you sign this form and enter the study, but later change 
your mind and withdraw your permission, you will be removed from the study at that 
time.  To withdraw your permission, please contact the Principal Investigator or study 
personnel at [omitted]. 
 
You may refuse to sign this authorization. Refusing to sign will not affect the present or 
future care you receive at this institution and will not cause any penalty or loss of benefits 
to which you are entitled.  However, if you do not sign this authorization form, you will 
not be able to take part in the study for which you are being considered.  You will receive 
a copy of this signed and dated authorization prior to your participation in this study. 
 
 
I agree that my personal health information may be used for the study purposes described 
in this form. 
 
 
 
Signature of Patient  
 
 
 
 
 Date 
 
Signature of Investigator Obtaining 
Authorization 
 Date 
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APPENDIX C 
 
EXPERIMENTAL RESEARCH SUBJECTS BILL OF RIGHTS 
California law, under Health & Safety Code §24172, requires that any person asked to 
take part as a subject in research involving a medical experiment, or any person asked to 
consent to such participation on behalf of another, is entitled to receive the following list 
of rights written in a language in which the person is fluent. This list includes the right to:  
. Be informed of the nature and purpose of the experiment.    
. Be given an explanation of the procedures to be followed in the medical experiment, 
and any drug or device to be utilized.    
. Be given a description of any attendant discomforts and risks reasonably to be expected 
from the experiment.    
. Be given an explanation of any benefits to the subject reasonably to be expected from 
the experiment, if applicable.    
. Be given a disclosure of any appropriate alternative procedures, drugs or devices that 
might be advantageous to the subject, and their relative risks and benefits.    
. Be informed of the avenues of medical treatment, if any, available to the subject after 
the experiment if complications should arise.    
. Be given an opportunity to ask any questions concerning the experiment or the 
procedures involved.    
. Be instructed that consent to participate in the medical experiment may be withdrawn 
at any time and the subject may discontinue participation in the medical 
experiment without prejudice.    
. Be given a copy of the signed and dated written consent form.    
. Be given the opportunity to decide to consent or not to consent to a medical experiment 
without the intervention of any element of force, fraud, deceit, duress, coercion, 
or undue influence on the subject’s decision.  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APPENDIX D 
 
INCLUSION CRITERIA CHECKLIST 
 
The potential participant:                    [checkmark if statement is true] 
 
 
Is 18-89 years old             ______________ 
 
Speaks English fluently       ______________ 
 
Is not globally aphasic     ______________ 
 
Is not on warfarin (Coumadin)           ______________ 
 
Has not suffered an intracerebral hemorrhage  
in past 6 months             ______________ 
 
Has not had neurosurgery in the past month         ______________ 
 
Is not pregnant             ______________ 
  
Has at least 6 years of education (i.e., completed 
the 6th grade)         ______________ 
 
Does not have a history of traumatic brain injury    ______________ 
  
Does not have a neurologic condition with known 
cognitive impact (e.g., dementia)    ______________ 
 
Does not have active renal disease      ______________ 
 
Does not have active liver disease      ______________ 
 
Does not have a history of allergy to pomegranate 
products         ______________ 
 
 
 
If all items are check marked, the patient is eligible for study participation. 
 
 
Thank you! 
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APPENDIX E 
 
WORK FLOW FOR RESIDENT 
 
 
1. Screen new admissions for eligibility by checking the unit lists each day. 
 
2. If a newly admitted patient is eligible (i.e., admitted due to an ischemic  
stroke), visit with patient and follow Initial Patient Visit Script (see next page). 
3. After meeting with the patient, review medical record to confirm inclusion criteria 
is met (i.e., that the patient is not on Coumadin, does not have active renal or liver 
disease, etc.). 
 
4. If patient still meets inclusion criteria, contact Dr. Kim to request an order  
for neuropsychology.  Also email the team [omitted], notifying them that a 
particular patient has met criteria for study inclusion and has consented. 
 
5. Fax the completed (just top portion) Nursing Authorization form to 44039.  Form 
is included at the end of this packet. 
 
6. Make a copy of the informed consent document and give it to the East Campus 
pharmacy (near unit 1100). 
 
7. Place all the original documents under Dr. Fogel’s office door (room 109 near the 
South Entrance). 
 
8. Change patient’s status to research active in LLEAP (specific instructions 
included at end of this packet). 
 
9. Add visit specifics (dates and whether person consented, declined, or did not meet 
criteria) to excel sheet. 
 
 
Who to contact: If you have any questions or concerns, please contact John Bellone, 
M.A., at jbellone@llu.edu. 
 
Thank you! 
  
 113 
APPENDIX F 
 
INITIAL PATIENT VISIT SCRIPT 
 
1) “Hi Mr./Ms. _________, I’m Dr. Jorge, I’m part of your medical team.  Do you 
know why you’re in the hospital? [if not, say “well, you had a stroke, which 
means that blood wasn’t getting to a part of your brain for a period of time”]  
Sometimes after a stroke people can experience changes in their thinking 
ability, like in memory, attention, language.  The reason why I’m meeting with 
you today is because you’ve been chosen to participate in a research study 
going on here at the hospital with stroke patients.  We’re interested in finding 
ways to help people improve their thinking skills, since there aren’t many 
treatments available for that.  Are you interested in hearing more about the 
study?” 
 
2) If yes, say “ok, great, but first I have to ask you a few questions and give you 
a quick screening measure to make sure you qualify…it’ll take just a couple 
minutes”; go over Inclusion Criteria Checklist with the patient. 
 
3) If they appear to meet the criteria, administer the MMSE (skip down to #4).  If 
they don’t meet criteria, say “I’m sorry, but based on this information you do not 
meet criteria for participating in this study.  Please ask your doctor for a 
referral to neuropsychology if you would like to receive cognitive testing.  You 
can also ask your doctor for a referral to a nutritionist if you would like.” 
 
4) If they attain a total score of 18 or above on the MMSE, go to #5.  If they attain a 
total score below 18, read the script listed in #3 and discontinue. 
 
5) Hand them one copy of the California Experimental Subject’s Bill of Rights, saying 
“This document explains your rights as a potential participant.”  Then read the 
page to them and have them sign your copy, indicating that they understand their 
rights.  
 
6) Hand them one copy the informed consent document, saying “Now I’ll tell you 
about the study, what we would ask you to do, and what the potential risks 
and benefits are.”  Then read it to them and provide opportunities for them to ask 
any questions they may have.  If they agree to participate, have them sign/date the 
bottom and initial/date each page on your form (tell them the correct date if they 
don’t know); then you sign your form. 
 
7) Give them a copy of the Authorization for Use of Protected Health Information 
form, saying “This is the last form I have for you.  It has to do with how your 
medical information can be used.”  Then read it to them and have them sign 
yours, and you sign yours. 
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8) Say “I’ll go make a copy of these forms so you can keep them.  I’ll be right 
back.” 
 
9) When you return, say “Here are your copies.  Thank you so much for your 
involvement in this.  A member of the neuropsychology team will meet with 
you within the next couple days to do some brief testing.  If, in the meantime, 
you have any questions or concerns, please let your doctor and nurses know 
or call the number on that form I gave you.  Thanks.” 
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APPENDIX G 
 
STUDY PROCEDURE FOR NEUROPSYCHOLOGY 
 
 
1) Paolo Jorge (Dr. Kim’s resident) will email Dr. Fogel and Jeff to inform that a 
particular patient has been admitted who meets the study’s inclusion criteria, and 
will place the original consent forms under Dr. Fogel’s office door.  He will also 
contact Dr. Kim to have her place an order for NP to see the patient for research 
purposes. 
 
2) NP should schedule Jeff for a 1-hour appointment with the patient at the earliest 
convenience to complete the baseline NP battery. 
 
3) Print an NP time 1 battery at one of the computers on 1500 or 1100 and 
administer to the patient.  Put only the subject number (e.g., subject 1) on the 
record form, not any protected health information. 
 
4) Fax the informed consent document, Authorization for Use of PHI document, and 
CA Experimental Subject’s Bill of Rights form (from the packet Paolo Jorge 
placed under Dr. Fogel’s door) using one of the fax machines near a nursing 
station to [omitted]. 
 
5) Using the copying machine in room 117, scan/email the NP packet (not scored) to 
John at jbellone@llu.edu.  Also, scan/email the 3 signed consenting documents 
and MMSE (from the packet Paolo Jorge placed under Dr. Fogel’s door) in a 
separate email to John at jbellone@llu.edu. 
 
6) Put the completed NP packet in the file cabinet in room 111.  If the office is 
unavailable, place it in Dr. Fogel’s box near the reception desk in the lobby. 
 
7) Email Dr. Kim to inform her the NP time 1 testing is completed so she can put in 
the order for pharmacy to begin treatment administration. 
 
8) Schedule Jeff for a 1-hour appointment with the patient 16 days after the time 1 
testing, unless you discover the patient is being discharged early, in which case 
administer the time 2 battery prior to discharge. 
 
9) The time 2 battery and script can be printed on unit 1500 or 1100. 
 
10) After completing time 2 administration, use the copying machine in room 117 to 
scan/email the packet (again, not scored) to John (jbellone@llu.edu), and place 
the forms in the file cabinet in room 111. 
 
Thank you! 
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APPENDIX H 
 
STUDY INFORMATION SHEET FOR NURSING STAFF 
 
 
What we are doing: We are examining whether dietary supplementation with an 
antioxidant (pomegranate extract) can help promote healthy cognitive functioning (i.e., 
thinking ability, such as memory or attention) as a component of recovery after stroke. 
 
Which patients are eligible: In order for patients to participate, they must have suffered 
a recent ischemic stroke, be an inpatient at LLUMC Rehabilitation Institute, be between 
ages 18-89, speak English fluently, have at least 6 years of education, be able to speak 
and understand language, have no history of allergy to pomegranates, have not had a 
cerebral hemorrhage in the past 6 months, not be on warfarin (Coumadin), have not 
undergone brain surgery in the past month, have no history of traumatic brain injury, 
have no history of neurodegenerative disease or neurologic condition with known 
cognitive impact, and have no active renal disease or liver disease. 
 
What patients are being asked to do: We will randomly assign patients to either receive 
an antioxidant supplement or a placebo capsule, and they will be administered this 
treatment twice per day for two weeks during their hospital stay. Neither the patient nor 
anyone at the hospital will know which pill the patient is receiving. The neuropsychology 
department will be conducting cognitive testing (about 1 hour of paper and pencil types 
of tests) before and after the two weeks of treatment to see if there is any improvement in 
thinking skills. 
 
What the potential risks are: Although there are no documented cases of negative 
effects of pomegranate products, there have been reports that this antioxidant has effects 
similar to aspirin and causes blood to clot less easily, which could increase the risk of 
bleeding. Also, it is possible that some individuals may experience an allergic reaction or 
potential interactions between the supplement and the medicines they are taking. We 
have taken extra measures to reduce these risks, and do not anticipate anything of this 
nature happening to the study participants. 
 
What your role is: Everything should be taken care of by study staff, which includes the 
neuropsychology department, pharmacy department, and select physicians. Nursing 
staff’s role will be to administer the pill provided by the pharmacy (either the antioxidant 
or placebo) with the patient’s 9am and 9pm medications. Please treat the patient like any 
other patient on the unit, but keep an eye out for any potential negative effects of the 
treatment (discussed above). If anything like that occurs, please contact a physician 
immediately and call one of the numbers listed below to inform study staff of the 
incident. Also, please do not attempt to discover which treatment the patient is receiving, 
and try not to let family members see the capsule’s appearance.  
 
Who to contact: If you have any questions or concerns, please call either John Bellone, 
M.A., at [omitted] or Rich Hartman, Ph.D., at [omitted]. 
